<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413660</url>
  </required_header>
  <id_info>
    <org_study_id>A3921025</org_study_id>
    <nct_id>NCT00413660</nct_id>
  </id_info>
  <brief_title>Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6
      dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with
      active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 response: &gt;= 20% improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET)</time_frame>
    <description>ACR20 response: &gt;= 20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</measure>
    <time_frame>Baseline up to Week 2, 4, 6, 8, 12</time_frame>
    <description>ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joints Count (TJC)</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joints Count (SJC)</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and more than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (&lt;) 2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
    <description>DAS28-3 (CRP) defined remission was classified as a score of &lt;2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, Week 12, 24/ET</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET</measure>
    <time_frame>Baseline, Week 12, 24/ET</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score</measure>
    <time_frame>Baseline, Week 12, 24/ET</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET</measure>
    <time_frame>Baseline, Week 12, 24/ET</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome Study- Sleep Scale (MOS-SS)</measure>
    <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
    <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
    <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range*100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale</measure>
    <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
    <description>FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET</measure>
    <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
    <description>FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>CP 690,550 1 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP 690,550 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP 690,550 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP 690,550 3 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP 690,550 5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dummy tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>4 blinded tablets administered BID</description>
    <arm_group_label>CP 690,550 1 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>4 blinded tablets administered BID</description>
    <arm_group_label>CP 690,550 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>4 blinded tablets administered BID</description>
    <arm_group_label>CP 690,550 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>4 blinded tablets administered BID</description>
    <arm_group_label>CP 690,550 3 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>4 blinded tablets administered BID</description>
    <arm_group_label>CP 690,550 5 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>CP-690,550 20 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active rheumatoid arthritis

          -  Inadequate response to stably dosed methotrexate

        Exclusion Criteria:

          -  Current therapy with any DMARD or biologic other than methotrexate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Debary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103-3692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206-1043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philladelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611-1124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-2308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Onalaska</city>
        <state>Wisconsin</state>
        <zip>54650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>(C1117ABH)</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1013AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1034ACO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74043-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04230-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia 1606</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providencia</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Viña Del Mar</city>
        <state>V Region</state>
        <zip>2570017</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 11 - Chodov</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Komarom</city>
        <zip>H-2921</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-759</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>81109</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jonkoping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921025&amp;StudyName=Comparison%20Of%206%20CP-690%2C550%20Doses%20Vs.Placebo%2C%20Each%20Combined%20With%20Methotrexate%2C%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <disposition_first_submitted>April 6, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 7, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2009</disposition_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMARD therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 1 mg</title>
          <description>CP-690,550 1 milligram (mg) tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 3 mg</title>
          <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>CP-690,550 20 mg</title>
          <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Placebo</title>
          <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
          <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="P9">
          <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
          <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="P10">
          <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
          <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="P11">
          <title>Placebo to CP-690,550 5 mg (R)</title>
          <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Up To Week 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="80"/>
                <participants group_id="P7" count="69"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="80"/>
                <participants group_id="P7" count="69"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="66"/>
                <participants group_id="P6" count="70"/>
                <participants group_id="P7" count="58"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post Week 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="66"/>
                <participants group_id="P6" count="57"/>
                <participants group_id="P7" count="40"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 1 mg</title>
          <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 3 mg</title>
          <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>CP-690,550 20 mg</title>
          <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Placebo</title>
          <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="75"/>
            <count group_id="B6" value="80"/>
            <count group_id="B7" value="69"/>
            <count group_id="B8" value="507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 44 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="40"/>
                    <measurement group_id="B8" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater Than or Equal to (&gt;=) 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="63"/>
                    <measurement group_id="B7" value="56"/>
                    <measurement group_id="B8" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>ACR20 response: &gt;= 20% improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Baseline Observation Carried Forward (BOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>ACR20 response: &gt;= 20% improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Baseline Observation Carried Forward (BOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="80"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.14"/>
                    <measurement group_id="O2" value="55.88"/>
                    <measurement group_id="O3" value="56.34"/>
                    <measurement group_id="O4" value="58.11"/>
                    <measurement group_id="O5" value="56.00"/>
                    <measurement group_id="O6" value="56.25"/>
                    <measurement group_id="O7" value="36.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 response: &gt;= 20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET)</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 response: &gt;= 20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="36.76"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="30.99"/>
                    <measurement group_id="O6" value="31.08"/>
                    <measurement group_id="O7" value="40.00"/>
                    <measurement group_id="O8" value="33.75"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="15.94"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.14"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="45.59"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="46.48"/>
                    <measurement group_id="O6" value="45.95"/>
                    <measurement group_id="O7" value="54.67"/>
                    <measurement group_id="O8" value="51.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="24.64"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.29"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="54.41"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="57.75"/>
                    <measurement group_id="O6" value="55.41"/>
                    <measurement group_id="O7" value="56.00"/>
                    <measurement group_id="O8" value="50.00"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="37.68"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="54.41"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="54.93"/>
                    <measurement group_id="O6" value="56.76"/>
                    <measurement group_id="O7" value="64.00"/>
                    <measurement group_id="O8" value="56.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="33.33"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="53.5"/>
                    <measurement group_id="O6" value="64.9"/>
                    <measurement group_id="O7" value="62.7"/>
                    <measurement group_id="O8" value="64.2"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="43.1"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="67.3"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="57.7"/>
                    <measurement group_id="O6" value="62.2"/>
                    <measurement group_id="O7" value="61.3"/>
                    <measurement group_id="O8" value="64.2"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="47.1"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="65.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="59.2"/>
                    <measurement group_id="O6" value="66.2"/>
                    <measurement group_id="O7" value="65.3"/>
                    <measurement group_id="O8" value="62.7"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="47.1"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.88"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="5.63"/>
                    <measurement group_id="O6" value="4.05"/>
                    <measurement group_id="O7" value="17.33"/>
                    <measurement group_id="O8" value="15.00"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="16.18"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="11.27"/>
                    <measurement group_id="O6" value="20.27"/>
                    <measurement group_id="O7" value="26.67"/>
                    <measurement group_id="O8" value="25.00"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="29.41"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="30.99"/>
                    <measurement group_id="O6" value="27.03"/>
                    <measurement group_id="O7" value="32.00"/>
                    <measurement group_id="O8" value="27.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="8.70"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.14"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="32.35"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="32.39"/>
                    <measurement group_id="O6" value="28.38"/>
                    <measurement group_id="O7" value="41.33"/>
                    <measurement group_id="O8" value="32.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="17.39"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.86"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="29.41"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="36.62"/>
                    <measurement group_id="O6" value="28.38"/>
                    <measurement group_id="O7" value="44.00"/>
                    <measurement group_id="O8" value="36.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="17.39"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="43.6"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="38.0"/>
                    <measurement group_id="O6" value="36.5"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="41.8"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="21.6"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="38.0"/>
                    <measurement group_id="O6" value="40.5"/>
                    <measurement group_id="O7" value="48.0"/>
                    <measurement group_id="O8" value="47.8"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="31.4"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="34.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="39.4"/>
                    <measurement group_id="O6" value="39.2"/>
                    <measurement group_id="O7" value="46.7"/>
                    <measurement group_id="O8" value="46.3"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="31.4"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here “n” is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="1.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.41"/>
                    <measurement group_id="O6" value="1.35"/>
                    <measurement group_id="O7" value="6.67"/>
                    <measurement group_id="O8" value="2.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.00"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="7.35"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.00"/>
                    <measurement group_id="O6" value="14.86"/>
                    <measurement group_id="O7" value="13.33"/>
                    <measurement group_id="O8" value="12.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.45"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="13.24"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="16.90"/>
                    <measurement group_id="O6" value="9.46"/>
                    <measurement group_id="O7" value="16.00"/>
                    <measurement group_id="O8" value="12.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.35"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="14.71"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="11.27"/>
                    <measurement group_id="O6" value="16.22"/>
                    <measurement group_id="O7" value="16.00"/>
                    <measurement group_id="O8" value="17.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="5.80"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="20.59"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="18.31"/>
                    <measurement group_id="O6" value="12.16"/>
                    <measurement group_id="O7" value="24.00"/>
                    <measurement group_id="O8" value="23.75"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="5.80"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="21.8"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="18.3"/>
                    <measurement group_id="O6" value="18.9"/>
                    <measurement group_id="O7" value="24.0"/>
                    <measurement group_id="O8" value="22.4"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="9.8"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="29.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="23.9"/>
                    <measurement group_id="O6" value="24.3"/>
                    <measurement group_id="O7" value="28.0"/>
                    <measurement group_id="O8" value="28.4"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="13.7"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="23.6"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="21.1"/>
                    <measurement group_id="O6" value="18.9"/>
                    <measurement group_id="O7" value="32.0"/>
                    <measurement group_id="O8" value="28.4"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="9.8"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</title>
        <description>ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant’s assessment of disease activity; participant’s global assessment of pain; physician’s assessment of disease activity; participant’s assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
        <time_frame>Baseline up to Week 2, 4, 6, 8, 12</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</title>
          <description>ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant’s assessment of disease activity; participant’s global assessment of pain; physician’s assessment of disease activity; participant’s assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Last Observation Carried Forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="80"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.07" spread="247.36"/>
                    <measurement group_id="O2" value="22.16" spread="243.19"/>
                    <measurement group_id="O3" value="4.47" spread="319.92"/>
                    <measurement group_id="O4" value="-21.34" spread="661.05"/>
                    <measurement group_id="O5" value="88.72" spread="287.91"/>
                    <measurement group_id="O6" value="36.55" spread="267.26"/>
                    <measurement group_id="O7" value="-113.31" spread="429.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.66" spread="622.43"/>
                    <measurement group_id="O2" value="163.40" spread="659.05"/>
                    <measurement group_id="O3" value="92.24" spread="919.49"/>
                    <measurement group_id="O4" value="7.29" spread="2038.26"/>
                    <measurement group_id="O5" value="341.52" spread="820.16"/>
                    <measurement group_id="O6" value="170.23" spread="825.49"/>
                    <measurement group_id="O7" value="-296.38" spread="1270.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.11" spread="948.25"/>
                    <measurement group_id="O2" value="442.29" spread="1087.57"/>
                    <measurement group_id="O3" value="348.96" spread="1446.07"/>
                    <measurement group_id="O4" value="111.83" spread="3626.48"/>
                    <measurement group_id="O5" value="716.69" spread="1285.36"/>
                    <measurement group_id="O6" value="402.21" spread="1428.69"/>
                    <measurement group_id="O7" value="-453.18" spread="2265.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.42" spread="1424.59"/>
                    <measurement group_id="O2" value="772.65" spread="1594.84"/>
                    <measurement group_id="O3" value="693.90" spread="1952.07"/>
                    <measurement group_id="O4" value="239.54" spread="5389.58"/>
                    <measurement group_id="O5" value="1154.14" spread="1733.13"/>
                    <measurement group_id="O6" value="725.67" spread="1954.96"/>
                    <measurement group_id="O7" value="-571.99" spread="3310.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="995.34" spread="2349.99"/>
                    <measurement group_id="O2" value="1511.40" spread="2711.76"/>
                    <measurement group_id="O3" value="1420.20" spread="3284.51"/>
                    <measurement group_id="O4" value="588.45" spread="8969.29"/>
                    <measurement group_id="O5" value="1974.18" spread="3231.70"/>
                    <measurement group_id="O6" value="1504.58" spread="2979.75"/>
                    <measurement group_id="O7" value="-755.22" spread="5107.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joints Count (TJC)</title>
        <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joints Count (TJC)</title>
          <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.64" spread="11.60"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="22.79" spread="10.57"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="21.46" spread="12.95"/>
                    <measurement group_id="O6" value="24.84" spread="12.51"/>
                    <measurement group_id="O7" value="23.68" spread="12.71"/>
                    <measurement group_id="O8" value="23.11" spread="12.67"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="21.59" spread="13.18"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.62" spread="12.09"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="17.71" spread="11.87"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="15.56" spread="10.44"/>
                    <measurement group_id="O6" value="17.34" spread="12.13"/>
                    <measurement group_id="O7" value="16.32" spread="13.18"/>
                    <measurement group_id="O8" value="15.33" spread="12.59"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="18.86" spread="13.00"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.01" spread="11.19"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="12.80" spread="10.36"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="13.06" spread="11.59"/>
                    <measurement group_id="O6" value="14.01" spread="14.73"/>
                    <measurement group_id="O7" value="13.00" spread="12.48"/>
                    <measurement group_id="O8" value="13.75" spread="13.08"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="16.17" spread="12.36"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.48" spread="12.18"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="11.12" spread="9.56"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="10.23" spread="10.44"/>
                    <measurement group_id="O6" value="13.55" spread="14.38"/>
                    <measurement group_id="O7" value="11.51" spread="12.67"/>
                    <measurement group_id="O8" value="13.22" spread="13.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="14.74" spread="13.86"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.24" spread="12.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="10.18" spread="10.30"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="9.82" spread="11.08"/>
                    <measurement group_id="O6" value="12.22" spread="13.75"/>
                    <measurement group_id="O7" value="9.49" spread="11.71"/>
                    <measurement group_id="O8" value="11.15" spread="13.76"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="13.57" spread="14.16"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="12.79"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="8.83" spread="9.61"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="10.09" spread="11.65"/>
                    <measurement group_id="O6" value="10.88" spread="12.79"/>
                    <measurement group_id="O7" value="10.18" spread="12.65"/>
                    <measurement group_id="O8" value="11.27" spread="13.68"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="13.77" spread="14.84"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.07" spread="9.11"/>
                    <measurement group_id="O2" value="19.33" spread="15.70"/>
                    <measurement group_id="O3" value="6.02" spread="7.97"/>
                    <measurement group_id="O4" value="19.15" spread="16.42"/>
                    <measurement group_id="O5" value="8.64" spread="12.25"/>
                    <measurement group_id="O6" value="9.77" spread="12.49"/>
                    <measurement group_id="O7" value="8.39" spread="11.32"/>
                    <measurement group_id="O8" value="7.07" spread="8.86"/>
                    <measurement group_id="O9" value="26.25" spread="19.07"/>
                    <measurement group_id="O10" value="8.51" spread="7.25"/>
                    <measurement group_id="O11" value="15.56" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" spread="11.06"/>
                    <measurement group_id="O2" value="13.76" spread="12.02"/>
                    <measurement group_id="O3" value="5.32" spread="6.35"/>
                    <measurement group_id="O4" value="15.00" spread="11.47"/>
                    <measurement group_id="O5" value="7.16" spread="9.91"/>
                    <measurement group_id="O6" value="8.27" spread="11.32"/>
                    <measurement group_id="O7" value="6.98" spread="9.96"/>
                    <measurement group_id="O8" value="6.51" spread="10.55"/>
                    <measurement group_id="O9" value="23.00" spread="16.59"/>
                    <measurement group_id="O10" value="7.62" spread="7.26"/>
                    <measurement group_id="O11" value="15.24" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="10.88"/>
                    <measurement group_id="O2" value="14.80" spread="14.09"/>
                    <measurement group_id="O3" value="5.52" spread="5.65"/>
                    <measurement group_id="O4" value="13.92" spread="9.93"/>
                    <measurement group_id="O5" value="6.85" spread="9.51"/>
                    <measurement group_id="O6" value="8.20" spread="9.94"/>
                    <measurement group_id="O7" value="6.37" spread="8.72"/>
                    <measurement group_id="O8" value="5.87" spread="7.68"/>
                    <measurement group_id="O9" value="21.67" spread="13.69"/>
                    <measurement group_id="O10" value="5.33" spread="5.74"/>
                    <measurement group_id="O11" value="15.88" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.68" spread="7.26"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-5.09" spread="9.91"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-6.06" spread="9.36"/>
                    <measurement group_id="O6" value="-7.62" spread="8.48"/>
                    <measurement group_id="O7" value="-7.68" spread="10.20"/>
                    <measurement group_id="O8" value="-7.78" spread="9.67"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.27" spread="7.50"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.28" spread="8.68"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-10.26" spread="9.63"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-8.42" spread="9.73"/>
                    <measurement group_id="O6" value="-10.77" spread="10.25"/>
                    <measurement group_id="O7" value="-10.90" spread="11.13"/>
                    <measurement group_id="O8" value="-9.59" spread="10.42"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-5.03" spread="10.05"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.86" spread="10.26"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-11.78" spread="10.82"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-11.01" spread="9.64"/>
                    <measurement group_id="O6" value="-11.07" spread="9.94"/>
                    <measurement group_id="O7" value="-12.14" spread="10.07"/>
                    <measurement group_id="O8" value="-10.58" spread="9.60"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-6.69" spread="11.68"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.08" spread="10.79"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-12.69" spread="11.57"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-11.50" spread="9.06"/>
                    <measurement group_id="O6" value="-11.93" spread="10.92"/>
                    <measurement group_id="O7" value="-13.76" spread="11.73"/>
                    <measurement group_id="O8" value="-12.26" spread="9.96"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-7.03" spread="13.26"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.67" spread="10.73"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-14.00" spread="12.56"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-10.88" spread="11.01"/>
                    <measurement group_id="O6" value="-13.47" spread="9.96"/>
                    <measurement group_id="O7" value="-14.24" spread="11.80"/>
                    <measurement group_id="O8" value="-12.77" spread="10.92"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-6.84" spread="12.84"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.05" spread="9.97"/>
                    <measurement group_id="O2" value="-6.81" spread="7.90"/>
                    <measurement group_id="O3" value="-17.44" spread="10.54"/>
                    <measurement group_id="O4" value="-1.00" spread="14.29"/>
                    <measurement group_id="O5" value="-12.93" spread="12.63"/>
                    <measurement group_id="O6" value="-14.58" spread="11.19"/>
                    <measurement group_id="O7" value="-15.05" spread="11.31"/>
                    <measurement group_id="O8" value="-15.65" spread="9.29"/>
                    <measurement group_id="O9" value="-2.33" spread="15.69"/>
                    <measurement group_id="O10" value="-10.16" spread="9.92"/>
                    <measurement group_id="O11" value="-8.06" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.64" spread="10.63"/>
                    <measurement group_id="O2" value="-12.38" spread="10.61"/>
                    <measurement group_id="O3" value="-18.36" spread="9.52"/>
                    <measurement group_id="O4" value="-5.15" spread="11.07"/>
                    <measurement group_id="O5" value="-14.58" spread="11.94"/>
                    <measurement group_id="O6" value="-16.08" spread="10.43"/>
                    <measurement group_id="O7" value="-16.64" spread="10.73"/>
                    <measurement group_id="O8" value="-15.67" spread="9.33"/>
                    <measurement group_id="O9" value="-5.58" spread="11.32"/>
                    <measurement group_id="O10" value="-11.05" spread="11.86"/>
                    <measurement group_id="O11" value="-8.24" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,21,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.53" spread="10.83"/>
                    <measurement group_id="O2" value="-10.40" spread="11.27"/>
                    <measurement group_id="O3" value="-18.16" spread="9.82"/>
                    <measurement group_id="O4" value="-6.23" spread="10.54"/>
                    <measurement group_id="O5" value="-14.93" spread="11.72"/>
                    <measurement group_id="O6" value="-16.36" spread="9.39"/>
                    <measurement group_id="O7" value="-17.03" spread="10.39"/>
                    <measurement group_id="O8" value="-16.36" spread="10.60"/>
                    <measurement group_id="O9" value="-6.92" spread="12.62"/>
                    <measurement group_id="O10" value="-13.17" spread="9.90"/>
                    <measurement group_id="O11" value="-7.59" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joints Count (SJC)</title>
        <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joints Count (SJC)</title>
          <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.51" spread="8.24"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="15.68" spread="8.56"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="14.06" spread="7.44"/>
                    <measurement group_id="O6" value="14.74" spread="7.46"/>
                    <measurement group_id="O7" value="15.33" spread="7.02"/>
                    <measurement group_id="O8" value="15.21" spread="8.04"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="15.72" spread="8.83"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.62" spread="7.81"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="10.97" spread="9.02"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="9.51" spread="6.30"/>
                    <measurement group_id="O6" value="10.14" spread="7.92"/>
                    <measurement group_id="O7" value="10.07" spread="7.29"/>
                    <measurement group_id="O8" value="10.14" spread="6.26"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="13.41" spread="9.47"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.85" spread="7.74"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="8.58" spread="8.20"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="8.01" spread="7.45"/>
                    <measurement group_id="O6" value="7.53" spread="6.98"/>
                    <measurement group_id="O7" value="7.85" spread="6.70"/>
                    <measurement group_id="O8" value="8.61" spread="7.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="11.11" spread="8.58"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="6.34"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="7.23" spread="7.28"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.22" spread="6.00"/>
                    <measurement group_id="O6" value="7.10" spread="7.62"/>
                    <measurement group_id="O7" value="6.60" spread="6.31"/>
                    <measurement group_id="O8" value="7.66" spread="7.43"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="10.39" spread="9.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.20" spread="7.84"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="6.63" spread="7.63"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="5.35" spread="5.03"/>
                    <measurement group_id="O6" value="6.78" spread="7.43"/>
                    <measurement group_id="O7" value="6.01" spread="6.22"/>
                    <measurement group_id="O8" value="7.22" spread="8.60"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="8.16" spread="8.02"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" spread="8.41"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.36" spread="6.64"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.13" spread="6.82"/>
                    <measurement group_id="O6" value="5.50" spread="5.84"/>
                    <measurement group_id="O7" value="4.85" spread="6.04"/>
                    <measurement group_id="O8" value="6.80" spread="8.87"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="8.79" spread="9.10"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="7.43"/>
                    <measurement group_id="O2" value="8.90" spread="7.55"/>
                    <measurement group_id="O3" value="3.49" spread="3.78"/>
                    <measurement group_id="O4" value="10.00" spread="10.51"/>
                    <measurement group_id="O5" value="3.84" spread="4.40"/>
                    <measurement group_id="O6" value="4.74" spread="5.64"/>
                    <measurement group_id="O7" value="4.26" spread="5.40"/>
                    <measurement group_id="O8" value="3.58" spread="3.54"/>
                    <measurement group_id="O9" value="14.50" spread="12.99"/>
                    <measurement group_id="O10" value="5.97" spread="5.98"/>
                    <measurement group_id="O11" value="8.63" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="7.82"/>
                    <measurement group_id="O2" value="7.33" spread="8.75"/>
                    <measurement group_id="O3" value="3.36" spread="5.19"/>
                    <measurement group_id="O4" value="8.54" spread="9.85"/>
                    <measurement group_id="O5" value="3.95" spread="5.80"/>
                    <measurement group_id="O6" value="4.21" spread="5.59"/>
                    <measurement group_id="O7" value="3.27" spread="4.02"/>
                    <measurement group_id="O8" value="3.31" spread="4.19"/>
                    <measurement group_id="O9" value="12.25" spread="8.25"/>
                    <measurement group_id="O10" value="5.00" spread="6.65"/>
                    <measurement group_id="O11" value="7.41" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="4.83"/>
                    <measurement group_id="O2" value="8.65" spread="8.77"/>
                    <measurement group_id="O3" value="3.73" spread="5.35"/>
                    <measurement group_id="O4" value="7.00" spread="7.14"/>
                    <measurement group_id="O5" value="3.71" spread="4.33"/>
                    <measurement group_id="O6" value="4.41" spread="6.86"/>
                    <measurement group_id="O7" value="3.03" spread="3.75"/>
                    <measurement group_id="O8" value="2.89" spread="2.97"/>
                    <measurement group_id="O9" value="11.25" spread="9.81"/>
                    <measurement group_id="O10" value="4.11" spread="3.90"/>
                    <measurement group_id="O11" value="7.94" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.43" spread="5.98"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-4.71" spread="7.40"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-4.24" spread="6.33"/>
                    <measurement group_id="O6" value="-4.75" spread="5.57"/>
                    <measurement group_id="O7" value="-5.45" spread="7.74"/>
                    <measurement group_id="O8" value="-5.04" spread="7.45"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.12" spread="5.00"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" spread="6.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-7.25" spread="8.80"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-5.97" spread="5.44"/>
                    <measurement group_id="O6" value="-7.34" spread="6.27"/>
                    <measurement group_id="O7" value="-7.64" spread="6.77"/>
                    <measurement group_id="O8" value="-6.74" spread="8.13"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-4.56" spread="5.61"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.41" spread="6.58"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-8.42" spread="9.28"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-7.68" spread="6.30"/>
                    <measurement group_id="O6" value="-7.68" spread="7.35"/>
                    <measurement group_id="O7" value="-8.68" spread="6.73"/>
                    <measurement group_id="O8" value="-7.97" spread="7.54"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-5.48" spread="6.91"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="8.13"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-9.03" spread="9.79"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-8.74" spread="6.94"/>
                    <measurement group_id="O6" value="-8.06" spread="7.40"/>
                    <measurement group_id="O7" value="-9.31" spread="7.51"/>
                    <measurement group_id="O8" value="-8.26" spread="8.30"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-7.15" spread="6.82"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="9.15"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-10.47" spread="9.71"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-8.13" spread="8.00"/>
                    <measurement group_id="O6" value="-9.20" spread="7.16"/>
                    <measurement group_id="O7" value="-10.68" spread="7.37"/>
                    <measurement group_id="O8" value="-8.84" spread="8.48"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-6.52" spread="8.28"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.67" spread="8.78"/>
                    <measurement group_id="O2" value="-5.95" spread="6.99"/>
                    <measurement group_id="O3" value="-13.00" spread="8.90"/>
                    <measurement group_id="O4" value="-2.46" spread="5.77"/>
                    <measurement group_id="O5" value="-10.60" spread="7.43"/>
                    <measurement group_id="O6" value="-9.95" spread="6.97"/>
                    <measurement group_id="O7" value="-10.66" spread="6.75"/>
                    <measurement group_id="O8" value="-10.65" spread="7.09"/>
                    <measurement group_id="O9" value="-5.83" spread="13.62"/>
                    <measurement group_id="O10" value="-8.65" spread="6.58"/>
                    <measurement group_id="O11" value="-6.88" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.95" spread="8.32"/>
                    <measurement group_id="O2" value="-7.52" spread="8.20"/>
                    <measurement group_id="O3" value="-13.36" spread="8.25"/>
                    <measurement group_id="O4" value="-3.92" spread="5.72"/>
                    <measurement group_id="O5" value="-10.39" spread="6.98"/>
                    <measurement group_id="O6" value="-10.48" spread="7.21"/>
                    <measurement group_id="O7" value="-11.61" spread="6.35"/>
                    <measurement group_id="O8" value="-11.00" spread="6.99"/>
                    <measurement group_id="O9" value="-8.08" spread="9.89"/>
                    <measurement group_id="O10" value="-9.62" spread="7.31"/>
                    <measurement group_id="O11" value="-7.88" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.15" spread="7.83"/>
                    <measurement group_id="O2" value="-6.60" spread="7.50"/>
                    <measurement group_id="O3" value="-13.00" spread="8.52"/>
                    <measurement group_id="O4" value="-5.46" spread="6.77"/>
                    <measurement group_id="O5" value="-10.25" spread="6.70"/>
                    <measurement group_id="O6" value="-10.48" spread="6.33"/>
                    <measurement group_id="O7" value="-11.70" spread="6.38"/>
                    <measurement group_id="O8" value="-11.57" spread="7.50"/>
                    <measurement group_id="O9" value="-9.08" spread="11.99"/>
                    <measurement group_id="O10" value="-10.28" spread="7.46"/>
                    <measurement group_id="O11" value="-7.35" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,66,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.96" spread="25.67"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="55.05" spread="24.81"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="54.87" spread="26.68"/>
                    <measurement group_id="O6" value="56.66" spread="25.42"/>
                    <measurement group_id="O7" value="55.83" spread="22.85"/>
                    <measurement group_id="O8" value="59.61" spread="23.61"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="51.19" spread="27.72"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,67,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.53" spread="24.99"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="43.33" spread="23.26"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="44.35" spread="24.31"/>
                    <measurement group_id="O6" value="41.26" spread="22.18"/>
                    <measurement group_id="O7" value="37.82" spread="22.17"/>
                    <measurement group_id="O8" value="40.57" spread="27.24"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="46.91" spread="25.39"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.57" spread="24.99"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="37.83" spread="22.77"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="40.03" spread="24.25"/>
                    <measurement group_id="O6" value="39.34" spread="25.09"/>
                    <measurement group_id="O7" value="35.81" spread="23.88"/>
                    <measurement group_id="O8" value="34.39" spread="24.29"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="42.02" spread="24.40"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.74" spread="24.31"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="33.75" spread="25.06"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="33.33" spread="24.18"/>
                    <measurement group_id="O6" value="34.38" spread="23.15"/>
                    <measurement group_id="O7" value="32.97" spread="23.50"/>
                    <measurement group_id="O8" value="33.65" spread="25.47"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="42.21" spread="27.12"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.97" spread="23.33"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="28.81" spread="23.86"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="36.55" spread="25.00"/>
                    <measurement group_id="O6" value="34.60" spread="24.04"/>
                    <measurement group_id="O7" value="30.26" spread="22.20"/>
                    <measurement group_id="O8" value="31.16" spread="24.86"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="41.34" spread="26.45"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,65,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.92" spread="22.49"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="30.90" spread="24.44"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="28.88" spread="22.80"/>
                    <measurement group_id="O6" value="33.78" spread="25.50"/>
                    <measurement group_id="O7" value="31.48" spread="24.86"/>
                    <measurement group_id="O8" value="31.09" spread="26.57"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="41.02" spread="26.13"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.83" spread="18.65"/>
                    <measurement group_id="O2" value="40.38" spread="21.81"/>
                    <measurement group_id="O3" value="29.67" spread="24.13"/>
                    <measurement group_id="O4" value="39.31" spread="24.13"/>
                    <measurement group_id="O5" value="28.98" spread="22.15"/>
                    <measurement group_id="O6" value="30.33" spread="22.04"/>
                    <measurement group_id="O7" value="27.07" spread="20.76"/>
                    <measurement group_id="O8" value="24.56" spread="23.46"/>
                    <measurement group_id="O9" value="51.25" spread="21.95"/>
                    <measurement group_id="O10" value="30.08" spread="22.81"/>
                    <measurement group_id="O11" value="38.38" spread="24.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,43,13,57,65,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.28" spread="22.75"/>
                    <measurement group_id="O2" value="35.71" spread="22.42"/>
                    <measurement group_id="O3" value="26.63" spread="23.48"/>
                    <measurement group_id="O4" value="42.31" spread="28.61"/>
                    <measurement group_id="O5" value="25.91" spread="23.10"/>
                    <measurement group_id="O6" value="33.66" spread="24.02"/>
                    <measurement group_id="O7" value="24.69" spread="20.98"/>
                    <measurement group_id="O8" value="24.58" spread="26.24"/>
                    <measurement group_id="O9" value="43.92" spread="27.07"/>
                    <measurement group_id="O10" value="25.08" spread="21.19"/>
                    <measurement group_id="O11" value="33.00" spread="27.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53" spread="21.05"/>
                    <measurement group_id="O2" value="38.15" spread="26.27"/>
                    <measurement group_id="O3" value="25.98" spread="20.61"/>
                    <measurement group_id="O4" value="35.62" spread="28.27"/>
                    <measurement group_id="O5" value="24.45" spread="20.24"/>
                    <measurement group_id="O6" value="28.65" spread="21.11"/>
                    <measurement group_id="O7" value="24.47" spread="22.23"/>
                    <measurement group_id="O8" value="19.92" spread="18.27"/>
                    <measurement group_id="O9" value="35.33" spread="27.17"/>
                    <measurement group_id="O10" value="27.14" spread="21.17"/>
                    <measurement group_id="O11" value="33.65" spread="26.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=65,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.49" spread="24.31"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-11.00" spread="20.82"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-10.76" spread="26.22"/>
                    <measurement group_id="O6" value="-15.30" spread="25.46"/>
                    <measurement group_id="O7" value="-17.67" spread="24.58"/>
                    <measurement group_id="O8" value="-18.84" spread="25.59"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-4.55" spread="25.28"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,63,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.44" spread="26.39"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-17.11" spread="23.98"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-14.76" spread="24.06"/>
                    <measurement group_id="O6" value="-17.80" spread="30.25"/>
                    <measurement group_id="O7" value="-20.39" spread="28.95"/>
                    <measurement group_id="O8" value="-24.74" spread="26.39"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-9.26" spread="28.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,63,0,69,71,72,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.56" spread="31.29"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-22.71" spread="28.84"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-21.07" spread="29.07"/>
                    <measurement group_id="O6" value="-22.94" spread="29.71"/>
                    <measurement group_id="O7" value="-22.61" spread="28.87"/>
                    <measurement group_id="O8" value="-26.97" spread="26.15"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-8.61" spread="29.03"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,60,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.91" spread="26.68"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-26.23" spread="29.28"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-18.11" spread="29.71"/>
                    <measurement group_id="O6" value="-21.84" spread="30.42"/>
                    <measurement group_id="O7" value="-24.66" spread="30.16"/>
                    <measurement group_id="O8" value="-29.08" spread="27.13"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-9.97" spread="28.48"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,57,0,64,65,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.16" spread="28.49"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-24.39" spread="30.89"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-25.75" spread="29.47"/>
                    <measurement group_id="O6" value="-24.02" spread="27.96"/>
                    <measurement group_id="O7" value="-23.95" spread="29.90"/>
                    <measurement group_id="O8" value="-29.67" spread="28.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-10.30" spread="30.14"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.02" spread="31.75"/>
                    <measurement group_id="O2" value="-13.48" spread="25.66"/>
                    <measurement group_id="O3" value="-27.19" spread="24.93"/>
                    <measurement group_id="O4" value="-15.15" spread="21.97"/>
                    <measurement group_id="O5" value="-26.50" spread="28.81"/>
                    <measurement group_id="O6" value="-26.64" spread="25.04"/>
                    <measurement group_id="O7" value="-27.97" spread="29.32"/>
                    <measurement group_id="O8" value="-32.09" spread="24.84"/>
                    <measurement group_id="O9" value="-19.00" spread="29.73"/>
                    <measurement group_id="O10" value="-17.22" spread="35.13"/>
                    <measurement group_id="O11" value="-18.19" spread="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,41,13,57,65,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.54" spread="36.96"/>
                    <measurement group_id="O2" value="-18.14" spread="25.06"/>
                    <measurement group_id="O3" value="-32.37" spread="26.83"/>
                    <measurement group_id="O4" value="-12.15" spread="25.36"/>
                    <measurement group_id="O5" value="-29.54" spread="30.99"/>
                    <measurement group_id="O6" value="-22.78" spread="30.27"/>
                    <measurement group_id="O7" value="-30.97" spread="31.28"/>
                    <measurement group_id="O8" value="-32.95" spread="27.48"/>
                    <measurement group_id="O9" value="-26.33" spread="33.15"/>
                    <measurement group_id="O10" value="-22.22" spread="30.68"/>
                    <measurement group_id="O11" value="-21.82" spread="21.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,42,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.08" spread="32.62"/>
                    <measurement group_id="O2" value="-15.40" spread="24.78"/>
                    <measurement group_id="O3" value="-33.19" spread="25.68"/>
                    <measurement group_id="O4" value="-18.85" spread="24.73"/>
                    <measurement group_id="O5" value="-29.89" spread="30.87"/>
                    <measurement group_id="O6" value="-28.51" spread="28.01"/>
                    <measurement group_id="O7" value="-31.00" spread="31.88"/>
                    <measurement group_id="O8" value="-36.98" spread="27.86"/>
                    <measurement group_id="O9" value="-34.92" spread="31.74"/>
                    <measurement group_id="O10" value="-21.08" spread="32.99"/>
                    <measurement group_id="O11" value="-21.18" spread="26.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,79,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.47" spread="24.77"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="58.91" spread="22.94"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="54.62" spread="23.71"/>
                    <measurement group_id="O6" value="58.35" spread="23.14"/>
                    <measurement group_id="O7" value="56.09" spread="21.42"/>
                    <measurement group_id="O8" value="57.24" spread="25.64"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="51.88" spread="26.44"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.19" spread="22.93"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="41.96" spread="23.12"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.56" spread="22.89"/>
                    <measurement group_id="O6" value="42.32" spread="21.98"/>
                    <measurement group_id="O7" value="35.73" spread="21.46"/>
                    <measurement group_id="O8" value="41.80" spread="26.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="46.33" spread="25.02"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.87" spread="23.21"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="39.78" spread="22.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="38.94" spread="22.27"/>
                    <measurement group_id="O6" value="38.53" spread="24.49"/>
                    <measurement group_id="O7" value="34.76" spread="21.33"/>
                    <measurement group_id="O8" value="37.47" spread="25.17"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="41.21" spread="24.46"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.30" spread="22.34"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="36.08" spread="23.56"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="33.01" spread="24.06"/>
                    <measurement group_id="O6" value="35.41" spread="22.68"/>
                    <measurement group_id="O7" value="30.56" spread="21.87"/>
                    <measurement group_id="O8" value="34.86" spread="25.24"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="43.02" spread="25.14"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.06" spread="21.76"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="30.11" spread="22.38"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="36.50" spread="25.29"/>
                    <measurement group_id="O6" value="36.09" spread="24.38"/>
                    <measurement group_id="O7" value="30.61" spread="21.60"/>
                    <measurement group_id="O8" value="31.85" spread="25.35"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="40.64" spread="25.32"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,65,66,70,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.78" spread="22.91"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="34.42" spread="25.15"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="29.66" spread="21.69"/>
                    <measurement group_id="O6" value="35.05" spread="24.65"/>
                    <measurement group_id="O7" value="32.53" spread="24.48"/>
                    <measurement group_id="O8" value="30.76" spread="25.59"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.85" spread="25.75"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.76" spread="20.40"/>
                    <measurement group_id="O2" value="38.29" spread="19.76"/>
                    <measurement group_id="O3" value="29.84" spread="24.12"/>
                    <measurement group_id="O4" value="39.31" spread="27.48"/>
                    <measurement group_id="O5" value="30.62" spread="22.56"/>
                    <measurement group_id="O6" value="30.98" spread="22.06"/>
                    <measurement group_id="O7" value="26.59" spread="20.19"/>
                    <measurement group_id="O8" value="24.76" spread="22.53"/>
                    <measurement group_id="O9" value="50.67" spread="23.10"/>
                    <measurement group_id="O10" value="28.46" spread="22.69"/>
                    <measurement group_id="O11" value="37.63" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.85" spread="22.86"/>
                    <measurement group_id="O2" value="37.95" spread="23.62"/>
                    <measurement group_id="O3" value="28.16" spread="22.36"/>
                    <measurement group_id="O4" value="42.08" spread="27.48"/>
                    <measurement group_id="O5" value="26.07" spread="22.75"/>
                    <measurement group_id="O6" value="35.00" spread="23.51"/>
                    <measurement group_id="O7" value="24.90" spread="20.57"/>
                    <measurement group_id="O8" value="25.56" spread="23.20"/>
                    <measurement group_id="O9" value="44.42" spread="27.38"/>
                    <measurement group_id="O10" value="26.22" spread="21.09"/>
                    <measurement group_id="O11" value="36.94" spread="27.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.23" spread="21.42"/>
                    <measurement group_id="O2" value="38.55" spread="27.08"/>
                    <measurement group_id="O3" value="25.93" spread="22.22"/>
                    <measurement group_id="O4" value="38.23" spread="27.28"/>
                    <measurement group_id="O5" value="23.64" spread="21.82"/>
                    <measurement group_id="O6" value="29.66" spread="21.58"/>
                    <measurement group_id="O7" value="25.07" spread="23.20"/>
                    <measurement group_id="O8" value="21.85" spread="18.07"/>
                    <measurement group_id="O9" value="34.83" spread="27.04"/>
                    <measurement group_id="O10" value="28.25" spread="21.49"/>
                    <measurement group_id="O11" value="34.59" spread="27.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="78"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.57" spread="26.12"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-16.96" spread="20.11"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-12.37" spread="21.83"/>
                    <measurement group_id="O6" value="-16.74" spread="24.15"/>
                    <measurement group_id="O7" value="-20.25" spread="26.92"/>
                    <measurement group_id="O8" value="-15.38" spread="30.86"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-5.82" spread="24.96"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.90" spread="25.53"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-19.40" spread="25.40"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-15.70" spread="22.92"/>
                    <measurement group_id="O6" value="-20.76" spread="26.76"/>
                    <measurement group_id="O7" value="-21.82" spread="28.55"/>
                    <measurement group_id="O8" value="-19.04" spread="29.28"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-10.65" spread="27.81"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.71" spread="29.02"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-22.02" spread="25.83"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-20.81" spread="24.06"/>
                    <measurement group_id="O6" value="-24.03" spread="23.89"/>
                    <measurement group_id="O7" value="-25.26" spread="30.85"/>
                    <measurement group_id="O8" value="-22.99" spread="29.63"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-9.46" spread="23.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,72,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.35" spread="27.84"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-27.48" spread="26.13"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-17.44" spread="28.12"/>
                    <measurement group_id="O6" value="-22.58" spread="25.37"/>
                    <measurement group_id="O7" value="-24.81" spread="31.07"/>
                    <measurement group_id="O8" value="-25.92" spread="30.55"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-11.48" spread="25.89"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,65,66,69,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.78" spread="28.81"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-23.95" spread="29.82"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-24.30" spread="24.57"/>
                    <measurement group_id="O6" value="-24.77" spread="26.21"/>
                    <measurement group_id="O7" value="-23.08" spread="30.87"/>
                    <measurement group_id="O8" value="-28.09" spread="30.23"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-12.75" spread="28.20"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,53,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.60" spread="31.45"/>
                    <measurement group_id="O2" value="-15.86" spread="22.28"/>
                    <measurement group_id="O3" value="-28.00" spread="28.15"/>
                    <measurement group_id="O4" value="-22.00" spread="26.01"/>
                    <measurement group_id="O5" value="-24.05" spread="28.00"/>
                    <measurement group_id="O6" value="-27.97" spread="24.02"/>
                    <measurement group_id="O7" value="-28.90" spread="29.36"/>
                    <measurement group_id="O8" value="-29.68" spread="31.20"/>
                    <measurement group_id="O9" value="-13.67" spread="35.93"/>
                    <measurement group_id="O10" value="-20.97" spread="31.57"/>
                    <measurement group_id="O11" value="-14.81" spread="17.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,43,13,57,66,59,54,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.56" spread="31.99"/>
                    <measurement group_id="O2" value="-16.19" spread="24.18"/>
                    <measurement group_id="O3" value="-30.93" spread="25.67"/>
                    <measurement group_id="O4" value="-19.23" spread="28.78"/>
                    <measurement group_id="O5" value="-28.33" spread="26.93"/>
                    <measurement group_id="O6" value="-23.95" spread="27.82"/>
                    <measurement group_id="O7" value="-31.12" spread="32.09"/>
                    <measurement group_id="O8" value="-30.67" spread="31.38"/>
                    <measurement group_id="O9" value="-19.92" spread="34.52"/>
                    <measurement group_id="O10" value="-23.22" spread="27.31"/>
                    <measurement group_id="O11" value="-13.53" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.68" spread="29.89"/>
                    <measurement group_id="O2" value="-15.30" spread="32.99"/>
                    <measurement group_id="O3" value="-32.11" spread="25.76"/>
                    <measurement group_id="O4" value="-23.08" spread="31.06"/>
                    <measurement group_id="O5" value="-29.84" spread="27.59"/>
                    <measurement group_id="O6" value="-28.61" spread="25.31"/>
                    <measurement group_id="O7" value="-30.83" spread="32.96"/>
                    <measurement group_id="O8" value="-33.04" spread="32.02"/>
                    <measurement group_id="O9" value="-29.50" spread="32.33"/>
                    <measurement group_id="O10" value="-21.92" spread="27.51"/>
                    <measurement group_id="O11" value="-15.88" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment of Arthritis</title>
        <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment of Arthritis</title>
          <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.66" spread="16.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="57.50" spread="18.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="56.51" spread="19.00"/>
                    <measurement group_id="O6" value="60.77" spread="16.75"/>
                    <measurement group_id="O7" value="60.51" spread="14.26"/>
                    <measurement group_id="O8" value="58.75" spread="17.90"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="58.30" spread="15.25"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.49" spread="21.64"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="41.07" spread="19.88"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.29" spread="20.12"/>
                    <measurement group_id="O6" value="42.85" spread="19.42"/>
                    <measurement group_id="O7" value="35.99" spread="15.97"/>
                    <measurement group_id="O8" value="41.92" spread="22.30"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="49.05" spread="18.00"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.69" spread="21.31"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="36.92" spread="21.20"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="34.73" spread="17.40"/>
                    <measurement group_id="O6" value="33.56" spread="19.77"/>
                    <measurement group_id="O7" value="33.35" spread="19.24"/>
                    <measurement group_id="O8" value="32.96" spread="22.38"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="40.23" spread="19.43"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.38" spread="17.11"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="31.51" spread="21.25"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="27.78" spread="18.40"/>
                    <measurement group_id="O6" value="30.82" spread="19.95"/>
                    <measurement group_id="O7" value="27.08" spread="17.28"/>
                    <measurement group_id="O8" value="32.65" spread="23.41"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="37.85" spread="21.03"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71" spread="21.03"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="26.60" spread="20.34"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="27.26" spread="19.97"/>
                    <measurement group_id="O6" value="28.01" spread="19.90"/>
                    <measurement group_id="O7" value="23.06" spread="17.18"/>
                    <measurement group_id="O8" value="27.70" spread="21.09"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.66" spread="21.39"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=63,0,59,0,64,66,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.65" spread="20.06"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="26.17" spread="21.33"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="24.77" spread="18.80"/>
                    <measurement group_id="O6" value="26.47" spread="19.69"/>
                    <measurement group_id="O7" value="23.28" spread="17.89"/>
                    <measurement group_id="O8" value="28.93" spread="23.44"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.70" spread="24.86"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.95" spread="16.25"/>
                    <measurement group_id="O2" value="44.19" spread="24.68"/>
                    <measurement group_id="O3" value="19.77" spread="19.74"/>
                    <measurement group_id="O4" value="33.31" spread="22.97"/>
                    <measurement group_id="O5" value="23.67" spread="21.04"/>
                    <measurement group_id="O6" value="23.00" spread="18.60"/>
                    <measurement group_id="O7" value="19.31" spread="15.80"/>
                    <measurement group_id="O8" value="18.60" spread="15.00"/>
                    <measurement group_id="O9" value="48.42" spread="30.00"/>
                    <measurement group_id="O10" value="26.22" spread="18.43"/>
                    <measurement group_id="O11" value="27.44" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.44" spread="18.10"/>
                    <measurement group_id="O2" value="34.29" spread="16.64"/>
                    <measurement group_id="O3" value="20.91" spread="18.21"/>
                    <measurement group_id="O4" value="32.92" spread="25.15"/>
                    <measurement group_id="O5" value="20.65" spread="18.68"/>
                    <measurement group_id="O6" value="24.05" spread="18.32"/>
                    <measurement group_id="O7" value="16.19" spread="12.41"/>
                    <measurement group_id="O8" value="18.84" spread="18.42"/>
                    <measurement group_id="O9" value="44.67" spread="25.31"/>
                    <measurement group_id="O10" value="21.95" spread="18.03"/>
                    <measurement group_id="O11" value="33.94" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.90" spread="16.51"/>
                    <measurement group_id="O2" value="36.53" spread="21.17"/>
                    <measurement group_id="O3" value="20.26" spread="18.12"/>
                    <measurement group_id="O4" value="32.54" spread="24.26"/>
                    <measurement group_id="O5" value="16.91" spread="14.67"/>
                    <measurement group_id="O6" value="21.25" spread="17.79"/>
                    <measurement group_id="O7" value="14.68" spread="13.07"/>
                    <measurement group_id="O8" value="14.49" spread="11.75"/>
                    <measurement group_id="O9" value="41.00" spread="31.58"/>
                    <measurement group_id="O10" value="20.67" spread="15.81"/>
                    <measurement group_id="O11" value="32.18" spread="19.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="68"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.88" spread="17.84"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-16.43" spread="19.20"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-14.60" spread="24.01"/>
                    <measurement group_id="O6" value="-17.88" spread="17.66"/>
                    <measurement group_id="O7" value="-24.30" spread="18.32"/>
                    <measurement group_id="O8" value="-16.61" spread="19.17"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-8.82" spread="13.20"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.66" spread="19.47"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-20.80" spread="22.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-22.00" spread="20.79"/>
                    <measurement group_id="O6" value="-27.67" spread="20.61"/>
                    <measurement group_id="O7" value="-27.43" spread="21.04"/>
                    <measurement group_id="O8" value="-25.31" spread="22.01"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-17.79" spread="18.95"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.02" spread="20.89"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-26.34" spread="24.05"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-28.80" spread="20.44"/>
                    <measurement group_id="O6" value="-30.39" spread="20.61"/>
                    <measurement group_id="O7" value="-33.26" spread="19.40"/>
                    <measurement group_id="O8" value="-25.93" spread="23.04"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-20.15" spread="22.19"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.50" spread="22.83"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-30.92" spread="22.85"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-29.67" spread="24.30"/>
                    <measurement group_id="O6" value="-33.63" spread="21.96"/>
                    <measurement group_id="O7" value="-37.26" spread="19.37"/>
                    <measurement group_id="O8" value="-30.66" spread="21.10"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-22.82" spread="22.89"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=63,0,59,0,64,66,66,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.76" spread="23.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-31.69" spread="24.30"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-31.58" spread="23.09"/>
                    <measurement group_id="O6" value="-34.98" spread="20.53"/>
                    <measurement group_id="O7" value="-36.80" spread="20.78"/>
                    <measurement group_id="O8" value="-30.27" spread="22.44"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-21.77" spread="24.51"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.33" spread="19.85"/>
                    <measurement group_id="O2" value="-16.95" spread="26.42"/>
                    <measurement group_id="O3" value="-39.23" spread="23.11"/>
                    <measurement group_id="O4" value="-23.85" spread="19.42"/>
                    <measurement group_id="O5" value="-33.47" spread="26.06"/>
                    <measurement group_id="O6" value="-38.45" spread="20.53"/>
                    <measurement group_id="O7" value="-39.70" spread="20.34"/>
                    <measurement group_id="O8" value="-38.65" spread="17.68"/>
                    <measurement group_id="O9" value="-19.08" spread="29.20"/>
                    <measurement group_id="O10" value="-29.89" spread="22.16"/>
                    <measurement group_id="O11" value="-32.56" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.21" spread="23.73"/>
                    <measurement group_id="O2" value="-26.86" spread="23.81"/>
                    <measurement group_id="O3" value="-38.70" spread="20.41"/>
                    <measurement group_id="O4" value="-24.23" spread="22.29"/>
                    <measurement group_id="O5" value="-36.81" spread="24.26"/>
                    <measurement group_id="O6" value="-37.41" spread="18.99"/>
                    <measurement group_id="O7" value="-43.42" spread="16.85"/>
                    <measurement group_id="O8" value="-38.16" spread="19.33"/>
                    <measurement group_id="O9" value="-22.83" spread="26.51"/>
                    <measurement group_id="O10" value="-34.16" spread="23.25"/>
                    <measurement group_id="O11" value="-26.29" spread="24.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.15" spread="22.39"/>
                    <measurement group_id="O2" value="-24.11" spread="24.91"/>
                    <measurement group_id="O3" value="-39.98" spread="21.13"/>
                    <measurement group_id="O4" value="-24.62" spread="19.99"/>
                    <measurement group_id="O5" value="-39.51" spread="22.83"/>
                    <measurement group_id="O6" value="-40.61" spread="20.10"/>
                    <measurement group_id="O7" value="-44.65" spread="16.76"/>
                    <measurement group_id="O8" value="-41.91" spread="17.09"/>
                    <measurement group_id="O9" value="-28.64" spread="31.29"/>
                    <measurement group_id="O10" value="-35.06" spread="21.26"/>
                    <measurement group_id="O11" value="-28.06" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,66,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.57"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="1.36" spread="0.75"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.44" spread="0.64"/>
                    <measurement group_id="O6" value="1.33" spread="0.60"/>
                    <measurement group_id="O7" value="1.41" spread="0.64"/>
                    <measurement group_id="O8" value="1.46" spread="0.58"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.20" spread="0.73"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.61"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="1.14" spread="0.75"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.20" spread="0.58"/>
                    <measurement group_id="O6" value="1.16" spread="0.61"/>
                    <measurement group_id="O7" value="1.15" spread="0.67"/>
                    <measurement group_id="O8" value="1.23" spread="0.63"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.15" spread="0.64"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.61"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="1.03" spread="0.69"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.13" spread="0.65"/>
                    <measurement group_id="O6" value="1.08" spread="0.64"/>
                    <measurement group_id="O7" value="1.12" spread="0.69"/>
                    <measurement group_id="O8" value="1.14" spread="0.65"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.14" spread="0.66"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,64,0,69,71,72,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.57"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.96" spread="0.69"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.03" spread="0.61"/>
                    <measurement group_id="O6" value="1.02" spread="0.65"/>
                    <measurement group_id="O7" value="1.05" spread="0.69"/>
                    <measurement group_id="O8" value="1.05" spread="0.65"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.07" spread="0.70"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,62,0,66,67,70,71,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.59"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.93" spread="0.68"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.06" spread="0.66"/>
                    <measurement group_id="O6" value="0.89" spread="0.67"/>
                    <measurement group_id="O7" value="0.98" spread="0.68"/>
                    <measurement group_id="O8" value="0.98" spread="0.72"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.05" spread="0.71"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,59,0,64,65,66,68,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.63"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.92" spread="0.75"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.94" spread="0.65"/>
                    <measurement group_id="O6" value="0.95" spread="0.68"/>
                    <measurement group_id="O7" value="0.96" spread="0.69"/>
                    <measurement group_id="O8" value="0.90" spread="0.67"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.08" spread="0.74"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.59"/>
                    <measurement group_id="O2" value="1.42" spread="0.64"/>
                    <measurement group_id="O3" value="0.82" spread="0.72"/>
                    <measurement group_id="O4" value="1.18" spread="0.77"/>
                    <measurement group_id="O5" value="0.92" spread="0.60"/>
                    <measurement group_id="O6" value="0.91" spread="0.68"/>
                    <measurement group_id="O7" value="0.97" spread="0.75"/>
                    <measurement group_id="O8" value="0.81" spread="0.67"/>
                    <measurement group_id="O9" value="1.36" spread="0.67"/>
                    <measurement group_id="O10" value="0.80" spread="0.64"/>
                    <measurement group_id="O11" value="1.05" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.58"/>
                    <measurement group_id="O2" value="1.33" spread="0.72"/>
                    <measurement group_id="O3" value="0.77" spread="0.68"/>
                    <measurement group_id="O4" value="1.13" spread="0.78"/>
                    <measurement group_id="O5" value="0.78" spread="0.57"/>
                    <measurement group_id="O6" value="0.84" spread="0.65"/>
                    <measurement group_id="O7" value="0.92" spread="0.72"/>
                    <measurement group_id="O8" value="0.75" spread="0.63"/>
                    <measurement group_id="O9" value="1.42" spread="0.62"/>
                    <measurement group_id="O10" value="0.73" spread="0.65"/>
                    <measurement group_id="O11" value="0.92" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,54,63,59,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.57"/>
                    <measurement group_id="O2" value="1.38" spread="0.74"/>
                    <measurement group_id="O3" value="0.85" spread="0.68"/>
                    <measurement group_id="O4" value="1.05" spread="0.84"/>
                    <measurement group_id="O5" value="0.78" spread="0.62"/>
                    <measurement group_id="O6" value="0.85" spread="0.66"/>
                    <measurement group_id="O7" value="0.88" spread="0.69"/>
                    <measurement group_id="O8" value="0.72" spread="0.61"/>
                    <measurement group_id="O9" value="1.34" spread="0.78"/>
                    <measurement group_id="O10" value="0.74" spread="0.66"/>
                    <measurement group_id="O11" value="0.95" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.38"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.23" spread="0.49"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.23" spread="0.41"/>
                    <measurement group_id="O6" value="-0.18" spread="0.42"/>
                    <measurement group_id="O7" value="-0.24" spread="0.40"/>
                    <measurement group_id="O8" value="-0.23" spread="0.45"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.05" spread="0.36"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=68,0,63,0,67,70,72,75,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.46"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.36" spread="0.52"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.32" spread="0.51"/>
                    <measurement group_id="O6" value="-0.25" spread="0.45"/>
                    <measurement group_id="O7" value="-0.31" spread="0.44"/>
                    <measurement group_id="O8" value="-0.34" spread="0.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.05" spread="0.46"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=66,0,62,0,69,71,72,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.45"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.39" spread="0.53"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.42" spread="0.54"/>
                    <measurement group_id="O6" value="-0.32" spread="0.57"/>
                    <measurement group_id="O7" value="-0.34" spread="0.47"/>
                    <measurement group_id="O8" value="-0.42" spread="0.52"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.13" spread="0.59"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=66,0,61,0,66,67,70,71,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.48"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.41" spread="0.63"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.40" spread="0.58"/>
                    <measurement group_id="O6" value="-0.43" spread="0.66"/>
                    <measurement group_id="O7" value="-0.39" spread="0.49"/>
                    <measurement group_id="O8" value="-0.50" spread="0.61"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.12" spread="0.55"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=64,0,58,0,64,65,66,68,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.48"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.48" spread="0.61"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.51" spread="0.61"/>
                    <measurement group_id="O6" value="-0.37" spread="0.63"/>
                    <measurement group_id="O7" value="-0.45" spread="0.50"/>
                    <measurement group_id="O8" value="-0.58" spread="0.61"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.10" spread="0.57"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.48"/>
                    <measurement group_id="O2" value="-0.16" spread="0.50"/>
                    <measurement group_id="O3" value="-0.59" spread="0.64"/>
                    <measurement group_id="O4" value="-0.08" spread="0.31"/>
                    <measurement group_id="O5" value="-0.52" spread="0.59"/>
                    <measurement group_id="O6" value="-0.41" spread="0.63"/>
                    <measurement group_id="O7" value="-0.45" spread="0.60"/>
                    <measurement group_id="O8" value="-0.62" spread="0.62"/>
                    <measurement group_id="O9" value="-0.46" spread="0.58"/>
                    <measurement group_id="O10" value="-0.30" spread="0.52"/>
                    <measurement group_id="O11" value="-0.01" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.47"/>
                    <measurement group_id="O2" value="-0.24" spread="0.42"/>
                    <measurement group_id="O3" value="-0.62" spread="0.68"/>
                    <measurement group_id="O4" value="-0.13" spread="0.41"/>
                    <measurement group_id="O5" value="-0.64" spread="0.62"/>
                    <measurement group_id="O6" value="-0.49" spread="0.58"/>
                    <measurement group_id="O7" value="-0.51" spread="0.59"/>
                    <measurement group_id="O8" value="-0.67" spread="0.65"/>
                    <measurement group_id="O9" value="-0.41" spread="0.55"/>
                    <measurement group_id="O10" value="-0.38" spread="0.54"/>
                    <measurement group_id="O11" value="-0.11" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,42,13,54,63,59,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.52"/>
                    <measurement group_id="O2" value="-0.21" spread="0.58"/>
                    <measurement group_id="O3" value="-0.53" spread="0.65"/>
                    <measurement group_id="O4" value="-0.21" spread="0.32"/>
                    <measurement group_id="O5" value="-0.61" spread="0.65"/>
                    <measurement group_id="O6" value="-0.47" spread="0.62"/>
                    <measurement group_id="O7" value="-0.53" spread="0.60"/>
                    <measurement group_id="O8" value="-0.66" spread="0.72"/>
                    <measurement group_id="O9" value="-0.48" spread="0.74"/>
                    <measurement group_id="O10" value="-0.37" spread="0.54"/>
                    <measurement group_id="O11" value="-0.08" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein (CRP)</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.30" spread="18.08"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="15.85" spread="19.34"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="18.03" spread="24.96"/>
                    <measurement group_id="O6" value="14.42" spread="17.81"/>
                    <measurement group_id="O7" value="17.21" spread="16.94"/>
                    <measurement group_id="O8" value="14.68" spread="17.19"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="18.88" spread="19.55"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.54" spread="19.53"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="8.20" spread="11.77"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.98" spread="10.05"/>
                    <measurement group_id="O6" value="5.24" spread="9.59"/>
                    <measurement group_id="O7" value="4.08" spread="4.79"/>
                    <measurement group_id="O8" value="8.35" spread="13.48"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="18.10" spread="20.41"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" spread="11.83"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="10.11" spread="15.29"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="8.63" spread="12.54"/>
                    <measurement group_id="O6" value="5.46" spread="9.76"/>
                    <measurement group_id="O7" value="4.63" spread="8.68"/>
                    <measurement group_id="O8" value="8.67" spread="13.62"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="15.30" spread="16.85"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="9.79"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="8.34" spread="13.70"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="8.26" spread="14.30"/>
                    <measurement group_id="O6" value="5.42" spread="10.04"/>
                    <measurement group_id="O7" value="5.41" spread="8.63"/>
                    <measurement group_id="O8" value="10.68" spread="17.49"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="15.18" spread="19.32"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" spread="11.78"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="7.64" spread="11.54"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="7.17" spread="11.47"/>
                    <measurement group_id="O6" value="10.18" spread="24.04"/>
                    <measurement group_id="O7" value="8.39" spread="11.39"/>
                    <measurement group_id="O8" value="9.75" spread="18.92"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="20.38" spread="30.37"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="9.59"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="9.54" spread="13.52"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.54" spread="9.68"/>
                    <measurement group_id="O6" value="9.11" spread="20.08"/>
                    <measurement group_id="O7" value="5.81" spread="7.25"/>
                    <measurement group_id="O8" value="9.53" spread="15.08"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="19.69" spread="20.07"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" spread="10.30"/>
                    <measurement group_id="O2" value="7.02" spread="8.51"/>
                    <measurement group_id="O3" value="10.72" spread="18.93"/>
                    <measurement group_id="O4" value="5.85" spread="5.47"/>
                    <measurement group_id="O5" value="5.40" spread="8.06"/>
                    <measurement group_id="O6" value="6.77" spread="10.27"/>
                    <measurement group_id="O7" value="9.79" spread="22.24"/>
                    <measurement group_id="O8" value="6.52" spread="11.33"/>
                    <measurement group_id="O9" value="6.89" spread="7.06"/>
                    <measurement group_id="O10" value="13.08" spread="11.49"/>
                    <measurement group_id="O11" value="6.52" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.96" spread="11.64"/>
                    <measurement group_id="O2" value="8.55" spread="12.87"/>
                    <measurement group_id="O3" value="7.71" spread="10.88"/>
                    <measurement group_id="O4" value="11.28" spread="17.83"/>
                    <measurement group_id="O5" value="7.93" spread="19.22"/>
                    <measurement group_id="O6" value="5.58" spread="8.69"/>
                    <measurement group_id="O7" value="3.46" spread="3.17"/>
                    <measurement group_id="O8" value="4.75" spread="5.28"/>
                    <measurement group_id="O9" value="7.89" spread="9.08"/>
                    <measurement group_id="O10" value="16.14" spread="16.63"/>
                    <measurement group_id="O11" value="12.10" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,43,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" spread="10.26"/>
                    <measurement group_id="O2" value="6.02" spread="7.31"/>
                    <measurement group_id="O3" value="10.31" spread="17.43"/>
                    <measurement group_id="O4" value="12.58" spread="12.19"/>
                    <measurement group_id="O5" value="5.92" spread="14.78"/>
                    <measurement group_id="O6" value="6.66" spread="17.03"/>
                    <measurement group_id="O7" value="6.51" spread="11.04"/>
                    <measurement group_id="O8" value="4.54" spread="4.69"/>
                    <measurement group_id="O9" value="7.19" spread="8.18"/>
                    <measurement group_id="O10" value="13.39" spread="15.05"/>
                    <measurement group_id="O11" value="16.21" spread="26.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="74"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="18.32"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-6.93" spread="14.85"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-11.38" spread="19.27"/>
                    <measurement group_id="O6" value="-9.19" spread="19.90"/>
                    <measurement group_id="O7" value="-11.87" spread="15.22"/>
                    <measurement group_id="O8" value="-6.56" spread="12.70"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.64" spread="14.26"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.07" spread="14.44"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-5.12" spread="17.24"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-8.54" spread="16.65"/>
                    <measurement group_id="O6" value="-9.45" spread="16.27"/>
                    <measurement group_id="O7" value="-11.70" spread="17.89"/>
                    <measurement group_id="O8" value="-6.69" spread="13.99"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-1.26" spread="12.51"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.92" spread="16.61"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-6.97" spread="17.77"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-9.81" spread="23.67"/>
                    <measurement group_id="O6" value="-9.38" spread="16.02"/>
                    <measurement group_id="O7" value="-10.73" spread="17.63"/>
                    <measurement group_id="O8" value="-5.03" spread="17.94"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.51" spread="12.72"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.94" spread="16.03"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-7.42" spread="14.21"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-11.35" spread="21.25"/>
                    <measurement group_id="O6" value="-4.97" spread="24.54"/>
                    <measurement group_id="O7" value="-8.67" spread="18.05"/>
                    <measurement group_id="O8" value="-6.11" spread="19.97"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.70" spread="25.55"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.56" spread="17.07"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-6.28" spread="14.07"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-12.52" spread="23.93"/>
                    <measurement group_id="O6" value="-5.96" spread="23.26"/>
                    <measurement group_id="O7" value="-10.18" spread="16.26"/>
                    <measurement group_id="O8" value="-5.71" spread="20.18"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.07" spread="15.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.96" spread="10.61"/>
                    <measurement group_id="O2" value="-11.26" spread="21.64"/>
                    <measurement group_id="O3" value="-7.04" spread="21.18"/>
                    <measurement group_id="O4" value="-6.33" spread="10.48"/>
                    <measurement group_id="O5" value="-11.53" spread="22.00"/>
                    <measurement group_id="O6" value="-8.18" spread="18.99"/>
                    <measurement group_id="O7" value="-7.01" spread="27.54"/>
                    <measurement group_id="O8" value="-8.16" spread="17.01"/>
                    <measurement group_id="O9" value="-7.59" spread="12.45"/>
                    <measurement group_id="O10" value="-2.59" spread="13.79"/>
                    <measurement group_id="O11" value="-13.44" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.21" spread="10.94"/>
                    <measurement group_id="O2" value="-9.73" spread="22.12"/>
                    <measurement group_id="O3" value="-11.31" spread="16.46"/>
                    <measurement group_id="O4" value="-0.90" spread="20.08"/>
                    <measurement group_id="O5" value="-7.80" spread="23.28"/>
                    <measurement group_id="O6" value="-9.60" spread="19.16"/>
                    <measurement group_id="O7" value="-14.21" spread="16.73"/>
                    <measurement group_id="O8" value="-9.65" spread="15.32"/>
                    <measurement group_id="O9" value="-10.22" spread="13.83"/>
                    <measurement group_id="O10" value="0.11" spread="15.15"/>
                    <measurement group_id="O11" value="-7.52" spread="20.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,43,43,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="11.78"/>
                    <measurement group_id="O2" value="-8.07" spread="10.28"/>
                    <measurement group_id="O3" value="-7.57" spread="22.26"/>
                    <measurement group_id="O4" value="0.40" spread="16.50"/>
                    <measurement group_id="O5" value="-8.18" spread="19.26"/>
                    <measurement group_id="O6" value="-8.72" spread="22.73"/>
                    <measurement group_id="O7" value="-10.65" spread="18.76"/>
                    <measurement group_id="O8" value="-8.75" spread="15.40"/>
                    <measurement group_id="O9" value="-10.92" spread="15.78"/>
                    <measurement group_id="O10" value="-2.16" spread="16.06"/>
                    <measurement group_id="O11" value="-3.41" spread="26.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
        <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and more than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (&lt;) 2.6 = remission.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
          <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and more than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (&lt;) 2.6 = remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,79,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="0.80"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.31" spread="0.95"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="5.14" spread="0.84"/>
                    <measurement group_id="O6" value="5.28" spread="0.85"/>
                    <measurement group_id="O7" value="5.39" spread="0.89"/>
                    <measurement group_id="O8" value="5.34" spread="0.87"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="5.26" spread="0.96"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=64,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="1.04"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.46" spread="1.03"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.26" spread="0.90"/>
                    <measurement group_id="O6" value="4.18" spread="1.04"/>
                    <measurement group_id="O7" value="4.18" spread="1.16"/>
                    <measurement group_id="O8" value="4.28" spread="1.07"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.91" spread="1.07"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="1.08"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.03" spread="1.17"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.03" spread="0.96"/>
                    <measurement group_id="O6" value="3.66" spread="1.12"/>
                    <measurement group_id="O7" value="3.75" spread="1.13"/>
                    <measurement group_id="O8" value="3.99" spread="1.11"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.60" spread="1.01"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="1.12"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.74" spread="1.30"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.68" spread="1.00"/>
                    <measurement group_id="O6" value="3.59" spread="1.27"/>
                    <measurement group_id="O7" value="3.60" spread="1.13"/>
                    <measurement group_id="O8" value="3.94" spread="1.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.35" spread="1.04"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.22"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.63" spread="1.27"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.54" spread="1.01"/>
                    <measurement group_id="O6" value="3.61" spread="1.23"/>
                    <measurement group_id="O7" value="3.38" spread="1.10"/>
                    <measurement group_id="O8" value="3.72" spread="1.35"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.30" spread="1.08"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="1.15"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.46" spread="1.38"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.57" spread="1.09"/>
                    <measurement group_id="O6" value="3.40" spread="1.27"/>
                    <measurement group_id="O7" value="3.28" spread="1.25"/>
                    <measurement group_id="O8" value="3.61" spread="1.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="4.37" spread="1.29"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.15"/>
                    <measurement group_id="O2" value="4.33" spread="1.16"/>
                    <measurement group_id="O3" value="3.11" spread="1.23"/>
                    <measurement group_id="O4" value="4.19" spread="1.48"/>
                    <measurement group_id="O5" value="3.19" spread="1.10"/>
                    <measurement group_id="O6" value="3.34" spread="1.22"/>
                    <measurement group_id="O7" value="3.12" spread="1.25"/>
                    <measurement group_id="O8" value="3.14" spread="1.06"/>
                    <measurement group_id="O9" value="4.65" spread="1.08"/>
                    <measurement group_id="O10" value="3.93" spread="1.06"/>
                    <measurement group_id="O11" value="3.91" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="1.28"/>
                    <measurement group_id="O2" value="3.83" spread="1.62"/>
                    <measurement group_id="O3" value="3.06" spread="1.25"/>
                    <measurement group_id="O4" value="4.24" spread="1.56"/>
                    <measurement group_id="O5" value="3.09" spread="1.17"/>
                    <measurement group_id="O6" value="3.14" spread="1.29"/>
                    <measurement group_id="O7" value="2.94" spread="1.04"/>
                    <measurement group_id="O8" value="3.08" spread="1.11"/>
                    <measurement group_id="O9" value="4.82" spread="1.24"/>
                    <measurement group_id="O10" value="3.81" spread="1.23"/>
                    <measurement group_id="O11" value="3.86" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="1.15"/>
                    <measurement group_id="O2" value="3.88" spread="1.49"/>
                    <measurement group_id="O3" value="3.14" spread="1.26"/>
                    <measurement group_id="O4" value="4.08" spread="1.35"/>
                    <measurement group_id="O5" value="3.03" spread="1.05"/>
                    <measurement group_id="O6" value="3.15" spread="1.19"/>
                    <measurement group_id="O7" value="2.91" spread="1.12"/>
                    <measurement group_id="O8" value="3.07" spread="0.98"/>
                    <measurement group_id="O9" value="4.51" spread="1.61"/>
                    <measurement group_id="O10" value="3.48" spread="1.06"/>
                    <measurement group_id="O11" value="4.08" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
        <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) &lt;2.6 = remission.</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET</title>
          <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) &lt;= 3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) &lt;2.6 = remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="73"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=64,0,63,0,63,69,68,73,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.76"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.78" spread="0.92"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.86" spread="0.82"/>
                    <measurement group_id="O6" value="-1.07" spread="0.84"/>
                    <measurement group_id="O7" value="-1.22" spread="1.08"/>
                    <measurement group_id="O8" value="-1.01" spread="0.97"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.26" spread="0.78"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=65,0,61,0,62,64,65,69,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="0.91"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-1.23" spread="1.19"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.09" spread="0.94"/>
                    <measurement group_id="O6" value="-1.58" spread="1.09"/>
                    <measurement group_id="O7" value="-1.71" spread="1.20"/>
                    <measurement group_id="O8" value="-1.30" spread="1.06"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.57" spread="0.88"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.03"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-1.52" spread="1.27"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.44" spread="0.99"/>
                    <measurement group_id="O6" value="-1.66" spread="1.18"/>
                    <measurement group_id="O7" value="-1.81" spread="1.17"/>
                    <measurement group_id="O8" value="-1.38" spread="1.07"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.80" spread="0.93"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.14"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-1.61" spread="1.18"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.56" spread="0.97"/>
                    <measurement group_id="O6" value="-1.63" spread="1.25"/>
                    <measurement group_id="O7" value="-2.02" spread="1.14"/>
                    <measurement group_id="O8" value="-1.63" spread="1.17"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.83" spread="1.11"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.13"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-1.85" spread="1.27"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.59" spread="1.18"/>
                    <measurement group_id="O6" value="-1.82" spread="1.17"/>
                    <measurement group_id="O7" value="-2.13" spread="1.32"/>
                    <measurement group_id="O8" value="-1.72" spread="1.13"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.82" spread="1.11"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.13"/>
                    <measurement group_id="O2" value="-1.14" spread="0.99"/>
                    <measurement group_id="O3" value="-2.27" spread="1.14"/>
                    <measurement group_id="O4" value="-0.81" spread="1.20"/>
                    <measurement group_id="O5" value="-1.93" spread="1.12"/>
                    <measurement group_id="O6" value="-1.89" spread="1.13"/>
                    <measurement group_id="O7" value="-2.31" spread="1.39"/>
                    <measurement group_id="O8" value="-2.13" spread="1.04"/>
                    <measurement group_id="O9" value="-0.88" spread="0.95"/>
                    <measurement group_id="O10" value="-1.14" spread="1.03"/>
                    <measurement group_id="O11" value="-1.43" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.26"/>
                    <measurement group_id="O2" value="-1.64" spread="1.25"/>
                    <measurement group_id="O3" value="-2.41" spread="1.26"/>
                    <measurement group_id="O4" value="-0.76" spread="1.22"/>
                    <measurement group_id="O5" value="-2.05" spread="1.15"/>
                    <measurement group_id="O6" value="-2.09" spread="1.28"/>
                    <measurement group_id="O7" value="-2.49" spread="1.26"/>
                    <measurement group_id="O8" value="-2.17" spread="0.96"/>
                    <measurement group_id="O9" value="-0.95" spread="0.81"/>
                    <measurement group_id="O10" value="-1.27" spread="1.37"/>
                    <measurement group_id="O11" value="-1.47" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.22"/>
                    <measurement group_id="O2" value="-1.55" spread="1.07"/>
                    <measurement group_id="O3" value="-2.29" spread="1.19"/>
                    <measurement group_id="O4" value="-0.92" spread="1.17"/>
                    <measurement group_id="O5" value="-2.06" spread="1.04"/>
                    <measurement group_id="O6" value="-2.13" spread="1.12"/>
                    <measurement group_id="O7" value="-2.49" spread="1.27"/>
                    <measurement group_id="O8" value="-2.19" spread="1.04"/>
                    <measurement group_id="O9" value="-1.26" spread="1.23"/>
                    <measurement group_id="O10" value="-1.55" spread="1.25"/>
                    <measurement group_id="O11" value="-1.25" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</title>
        <description>Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</title>
          <description>Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="74"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="9.5"/>
                    <measurement group_id="O6" value="13.0"/>
                    <measurement group_id="O7" value="16.2"/>
                    <measurement group_id="O8" value="12.2"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.9"/>
                    <measurement group_id="O6" value="46.4"/>
                    <measurement group_id="O7" value="50.0"/>
                    <measurement group_id="O8" value="41.9"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="23.0"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="50.8"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="47.6"/>
                    <measurement group_id="O6" value="40.6"/>
                    <measurement group_id="O7" value="33.8"/>
                    <measurement group_id="O8" value="44.6"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="73.8"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="16.1"/>
                    <measurement group_id="O6" value="28.1"/>
                    <measurement group_id="O7" value="30.8"/>
                    <measurement group_id="O8" value="21.4"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="8.2"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="48.4"/>
                    <measurement group_id="O6" value="53.1"/>
                    <measurement group_id="O7" value="49.2"/>
                    <measurement group_id="O8" value="42.9"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.4"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="35.5"/>
                    <measurement group_id="O6" value="18.8"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="34.3"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="57.4"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="29.5"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="31.8"/>
                    <measurement group_id="O6" value="29.9"/>
                    <measurement group_id="O7" value="31.8"/>
                    <measurement group_id="O8" value="23.2"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="12.1"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="42.6"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.4"/>
                    <measurement group_id="O6" value="50.7"/>
                    <measurement group_id="O7" value="50.0"/>
                    <measurement group_id="O8" value="44.9"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="43.1"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="27.9"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="25.8"/>
                    <measurement group_id="O6" value="19.4"/>
                    <measurement group_id="O7" value="18.2"/>
                    <measurement group_id="O8" value="31.9"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="44.8"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="30.5"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="37.1"/>
                    <measurement group_id="O6" value="32.3"/>
                    <measurement group_id="O7" value="43.3"/>
                    <measurement group_id="O8" value="37.3"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="13.8"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="47.5"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="46.8"/>
                    <measurement group_id="O6" value="45.2"/>
                    <measurement group_id="O7" value="47.8"/>
                    <measurement group_id="O8" value="40.3"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="46.6"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="22.0"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="16.1"/>
                    <measurement group_id="O6" value="22.6"/>
                    <measurement group_id="O7" value="9.0"/>
                    <measurement group_id="O8" value="22.4"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.7"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="41.3"/>
                    <measurement group_id="O7" value="51.6"/>
                    <measurement group_id="O8" value="36.9"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="32.7"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="39.7"/>
                    <measurement group_id="O7" value="37.1"/>
                    <measurement group_id="O8" value="44.6"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="36.7"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="21.8"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="19.0"/>
                    <measurement group_id="O7" value="11.3"/>
                    <measurement group_id="O8" value="18.5"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="46.7"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="19.0"/>
                    <measurement group_id="O3" value="55.8"/>
                    <measurement group_id="O4" value="30.8"/>
                    <measurement group_id="O5" value="51.9"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="48.3"/>
                    <measurement group_id="O8" value="52.7"/>
                    <measurement group_id="O9" value="11.1"/>
                    <measurement group_id="O10" value="27.0"/>
                    <measurement group_id="O11" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="38.1"/>
                    <measurement group_id="O3" value="32.6"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="37.0"/>
                    <measurement group_id="O6" value="34.4"/>
                    <measurement group_id="O7" value="43.1"/>
                    <measurement group_id="O8" value="43.6"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="40.5"/>
                    <measurement group_id="O11" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="46.2"/>
                    <measurement group_id="O5" value="11.1"/>
                    <measurement group_id="O6" value="15.6"/>
                    <measurement group_id="O7" value="8.6"/>
                    <measurement group_id="O8" value="3.6"/>
                    <measurement group_id="O9" value="55.6"/>
                    <measurement group_id="O10" value="32.4"/>
                    <measurement group_id="O11" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="59.1"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="61.4"/>
                    <measurement group_id="O6" value="52.4"/>
                    <measurement group_id="O7" value="57.9"/>
                    <measurement group_id="O8" value="52.7"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="30.6"/>
                    <measurement group_id="O11" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="46.2"/>
                    <measurement group_id="O5" value="28.1"/>
                    <measurement group_id="O6" value="36.5"/>
                    <measurement group_id="O7" value="35.1"/>
                    <measurement group_id="O8" value="40.0"/>
                    <measurement group_id="O9" value="58.3"/>
                    <measurement group_id="O10" value="36.1"/>
                    <measurement group_id="O11" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="10.5"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="7.0"/>
                    <measurement group_id="O8" value="7.3"/>
                    <measurement group_id="O9" value="41.7"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="54.8"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="52.8"/>
                    <measurement group_id="O6" value="58.7"/>
                    <measurement group_id="O7" value="66.1"/>
                    <measurement group_id="O8" value="59.6"/>
                    <measurement group_id="O9" value="25.0"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="37.7"/>
                    <measurement group_id="O6" value="30.2"/>
                    <measurement group_id="O7" value="23.2"/>
                    <measurement group_id="O8" value="34.6"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="41.7"/>
                    <measurement group_id="O11" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="11.9"/>
                    <measurement group_id="O4" value="38.5"/>
                    <measurement group_id="O5" value="9.4"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="10.7"/>
                    <measurement group_id="O8" value="5.8"/>
                    <measurement group_id="O9" value="41.7"/>
                    <measurement group_id="O10" value="25.0"/>
                    <measurement group_id="O11" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)</title>
        <description>DAS28-3 (CRP) defined remission was classified as a score of &lt;2.6.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 20, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)</title>
          <description>DAS28-3 (CRP) defined remission was classified as a score of &lt;2.6.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="68"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="74"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=64,0,63,0,63,68,68,74,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.17"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="1.59"/>
                    <measurement group_id="O6" value="4.41"/>
                    <measurement group_id="O7" value="13.24"/>
                    <measurement group_id="O8" value="4.05"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.28"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=65,0,61,0,62,63,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="14.75"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="8.06"/>
                    <measurement group_id="O6" value="19.05"/>
                    <measurement group_id="O7" value="16.92"/>
                    <measurement group_id="O8" value="10.00"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.28"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=63,0,61,0,66,66,66,69,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="19.67"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="13.64"/>
                    <measurement group_id="O6" value="24.24"/>
                    <measurement group_id="O7" value="22.73"/>
                    <measurement group_id="O8" value="10.14"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.45"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=63,0,59,0,62,61,67,67,0,58,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="22.03"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="19.35"/>
                    <measurement group_id="O6" value="21.31"/>
                    <measurement group_id="O7" value="23.88"/>
                    <measurement group_id="O8" value="20.90"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="6.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,55,0,60,62,62,65,0,60,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="30.91"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="16.67"/>
                    <measurement group_id="O6" value="32.26"/>
                    <measurement group_id="O7" value="37.10"/>
                    <measurement group_id="O8" value="24.62"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="6.67"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=42,21,43,13,54,63,58,55,9,37,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="24.1"/>
                    <measurement group_id="O6" value="30.2"/>
                    <measurement group_id="O7" value="37.9"/>
                    <measurement group_id="O8" value="29.1"/>
                    <measurement group_id="O9" value="11.1"/>
                    <measurement group_id="O10" value="8.1"/>
                    <measurement group_id="O11" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=39,21,44,13,57,62,57,55,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="35.1"/>
                    <measurement group_id="O6" value="37.1"/>
                    <measurement group_id="O7" value="38.6"/>
                    <measurement group_id="O8" value="30.9"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="13.9"/>
                    <measurement group_id="O11" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="35.7"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="41.5"/>
                    <measurement group_id="O6" value="36.5"/>
                    <measurement group_id="O7" value="39.3"/>
                    <measurement group_id="O8" value="32.7"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="19.4"/>
                    <measurement group_id="O11" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36)</title>
        <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
        <time_frame>Baseline, Week 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36)</title>
          <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.48" spread="10.33"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="33.20" spread="11.04"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="31.93" spread="9.66"/>
                    <measurement group_id="O6" value="31.92" spread="9.15"/>
                    <measurement group_id="O7" value="31.50" spread="9.29"/>
                    <measurement group_id="O8" value="30.23" spread="9.70"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.01" spread="11.06"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.53" spread="8.52"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="34.45" spread="10.52"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="35.54" spread="8.69"/>
                    <measurement group_id="O6" value="34.64" spread="10.72"/>
                    <measurement group_id="O7" value="33.70" spread="9.85"/>
                    <measurement group_id="O8" value="33.13" spread="9.32"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="37.23" spread="9.51"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.14" spread="6.60"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="34.60" spread="8.35"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="35.36" spread="8.23"/>
                    <measurement group_id="O6" value="35.11" spread="7.85"/>
                    <measurement group_id="O7" value="34.98" spread="8.19"/>
                    <measurement group_id="O8" value="34.20" spread="8.18"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.93" spread="8.71"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.08" spread="6.77"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.17" spread="8.02"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="35.12" spread="8.90"/>
                    <measurement group_id="O6" value="36.52" spread="9.28"/>
                    <measurement group_id="O7" value="35.94" spread="8.44"/>
                    <measurement group_id="O8" value="36.08" spread="8.48"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="36.50" spread="9.38"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.32" spread="9.95"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="42.36" spread="10.07"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="41.54" spread="9.39"/>
                    <measurement group_id="O6" value="42.60" spread="10.83"/>
                    <measurement group_id="O7" value="40.81" spread="11.75"/>
                    <measurement group_id="O8" value="40.97" spread="9.98"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="44.08" spread="11.63"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.76" spread="10.41"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="38.88" spread="11.35"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="37.72" spread="10.38"/>
                    <measurement group_id="O6" value="38.99" spread="10.80"/>
                    <measurement group_id="O7" value="38.01" spread="11.06"/>
                    <measurement group_id="O8" value="38.03" spread="10.70"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="40.09" spread="11.08"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.72" spread="11.55"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.18" spread="14.16"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="37.21" spread="12.51"/>
                    <measurement group_id="O6" value="36.23" spread="12.64"/>
                    <measurement group_id="O7" value="34.73" spread="14.42"/>
                    <measurement group_id="O8" value="35.13" spread="13.45"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.37" spread="13.94"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.98" spread="11.58"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="40.07" spread="11.65"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="41.88" spread="12.02"/>
                    <measurement group_id="O6" value="42.79" spread="10.99"/>
                    <measurement group_id="O7" value="39.68" spread="12.65"/>
                    <measurement group_id="O8" value="39.91" spread="12.53"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="42.91" spread="13.08"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.13" spread="6.72"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="33.73" spread="8.33"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="32.99" spread="8.03"/>
                    <measurement group_id="O6" value="32.96" spread="8.15"/>
                    <measurement group_id="O7" value="33.19" spread="7.31"/>
                    <measurement group_id="O8" value="32.11" spread="8.57"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.41" spread="8.59"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.39" spread="11.42"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="41.47" spread="12.68"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.81" spread="11.80"/>
                    <measurement group_id="O6" value="43.53" spread="11.00"/>
                    <measurement group_id="O7" value="40.92" spread="13.00"/>
                    <measurement group_id="O8" value="41.68" spread="12.17"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="44.72" spread="13.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.05" spread="10.73"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="36.49" spread="11.63"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="36.45" spread="9.78"/>
                    <measurement group_id="O6" value="36.25" spread="10.75"/>
                    <measurement group_id="O7" value="37.80" spread="10.76"/>
                    <measurement group_id="O8" value="37.49" spread="11.48"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="36.23" spread="11.37"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.47" spread="8.77"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="39.25" spread="10.85"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="38.26" spread="10.21"/>
                    <measurement group_id="O6" value="39.71" spread="9.69"/>
                    <measurement group_id="O7" value="39.41" spread="10.03"/>
                    <measurement group_id="O8" value="40.17" spread="10.41"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.79" spread="10.14"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.62" spread="8.02"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="42.76" spread="11.30"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.73" spread="9.57"/>
                    <measurement group_id="O6" value="44.00" spread="10.81"/>
                    <measurement group_id="O7" value="44.39" spread="9.40"/>
                    <measurement group_id="O8" value="44.21" spread="9.78"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.46" spread="10.15"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.85" spread="8.10"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="39.04" spread="8.74"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="40.11" spread="9.54"/>
                    <measurement group_id="O6" value="39.15" spread="8.76"/>
                    <measurement group_id="O7" value="40.05" spread="9.44"/>
                    <measurement group_id="O8" value="41.10" spread="9.78"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="39.54" spread="10.42"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.45" spread="9.82"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="46.80" spread="10.08"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="46.33" spread="10.59"/>
                    <measurement group_id="O6" value="45.99" spread="10.68"/>
                    <measurement group_id="O7" value="47.82" spread="10.24"/>
                    <measurement group_id="O8" value="46.03" spread="11.42"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="46.48" spread="12.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.18" spread="11.32"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="43.54" spread="11.20"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.28" spread="10.82"/>
                    <measurement group_id="O6" value="42.84" spread="10.06"/>
                    <measurement group_id="O7" value="43.93" spread="9.81"/>
                    <measurement group_id="O8" value="44.23" spread="10.53"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="41.38" spread="10.87"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.47" spread="12.12"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="39.14" spread="12.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="39.90" spread="12.87"/>
                    <measurement group_id="O6" value="39.01" spread="12.07"/>
                    <measurement group_id="O7" value="39.07" spread="11.96"/>
                    <measurement group_id="O8" value="41.33" spread="13.30"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="40.39" spread="12.49"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.84" spread="10.95"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="44.57" spread="10.95"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="45.34" spread="13.08"/>
                    <measurement group_id="O6" value="43.08" spread="9.84"/>
                    <measurement group_id="O7" value="45.24" spread="10.70"/>
                    <measurement group_id="O8" value="46.11" spread="11.49"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="43.36" spread="12.67"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.24" spread="8.19"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="38.70" spread="9.73"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="38.27" spread="9.31"/>
                    <measurement group_id="O6" value="39.52" spread="9.30"/>
                    <measurement group_id="O7" value="39.97" spread="8.98"/>
                    <measurement group_id="O8" value="39.64" spread="10.20"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="37.89" spread="9.94"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.86" spread="11.45"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="45.47" spread="11.10"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="45.84" spread="13.41"/>
                    <measurement group_id="O6" value="44.18" spread="10.26"/>
                    <measurement group_id="O7" value="45.61" spread="10.59"/>
                    <measurement group_id="O8" value="46.65" spread="11.64"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="45.08" spread="12.48"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.41" spread="10.35"/>
                    <measurement group_id="O2" value="34.30" spread="10.72"/>
                    <measurement group_id="O3" value="38.38" spread="11.35"/>
                    <measurement group_id="O4" value="39.39" spread="11.83"/>
                    <measurement group_id="O5" value="40.04" spread="10.81"/>
                    <measurement group_id="O6" value="38.19" spread="10.88"/>
                    <measurement group_id="O7" value="38.62" spread="11.08"/>
                    <measurement group_id="O8" value="40.51" spread="12.11"/>
                    <measurement group_id="O9" value="32.31" spread="11.36"/>
                    <measurement group_id="O10" value="39.44" spread="10.64"/>
                    <measurement group_id="O11" value="38.09" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.51" spread="8.53"/>
                    <measurement group_id="O2" value="35.06" spread="9.36"/>
                    <measurement group_id="O3" value="39.88" spread="11.85"/>
                    <measurement group_id="O4" value="38.96" spread="10.26"/>
                    <measurement group_id="O5" value="41.09" spread="9.12"/>
                    <measurement group_id="O6" value="40.32" spread="10.91"/>
                    <measurement group_id="O7" value="40.69" spread="9.67"/>
                    <measurement group_id="O8" value="41.97" spread="10.80"/>
                    <measurement group_id="O9" value="35.02" spread="10.72"/>
                    <measurement group_id="O10" value="44.27" spread="9.80"/>
                    <measurement group_id="O11" value="42.45" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.17" spread="8.68"/>
                    <measurement group_id="O2" value="39.57" spread="11.54"/>
                    <measurement group_id="O3" value="44.15" spread="10.31"/>
                    <measurement group_id="O4" value="43.07" spread="9.91"/>
                    <measurement group_id="O5" value="44.96" spread="9.23"/>
                    <measurement group_id="O6" value="44.52" spread="10.98"/>
                    <measurement group_id="O7" value="45.76" spread="9.67"/>
                    <measurement group_id="O8" value="46.89" spread="10.25"/>
                    <measurement group_id="O9" value="40.32" spread="11.00"/>
                    <measurement group_id="O10" value="43.11" spread="9.54"/>
                    <measurement group_id="O11" value="44.24" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.65" spread="7.40"/>
                    <measurement group_id="O2" value="36.87" spread="7.75"/>
                    <measurement group_id="O3" value="41.45" spread="10.05"/>
                    <measurement group_id="O4" value="37.35" spread="5.95"/>
                    <measurement group_id="O5" value="41.35" spread="10.23"/>
                    <measurement group_id="O6" value="41.09" spread="9.27"/>
                    <measurement group_id="O7" value="41.40" spread="9.24"/>
                    <measurement group_id="O8" value="44.03" spread="9.52"/>
                    <measurement group_id="O9" value="35.81" spread="11.52"/>
                    <measurement group_id="O10" value="43.16" spread="9.70"/>
                    <measurement group_id="O11" value="40.68" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.05" spread="10.69"/>
                    <measurement group_id="O2" value="39.60" spread="9.23"/>
                    <measurement group_id="O3" value="48.76" spread="11.25"/>
                    <measurement group_id="O4" value="47.29" spread="6.58"/>
                    <measurement group_id="O5" value="48.40" spread="10.41"/>
                    <measurement group_id="O6" value="47.55" spread="10.18"/>
                    <measurement group_id="O7" value="50.11" spread="11.68"/>
                    <measurement group_id="O8" value="50.50" spread="10.98"/>
                    <measurement group_id="O9" value="41.94" spread="13.65"/>
                    <measurement group_id="O10" value="49.75" spread="11.83"/>
                    <measurement group_id="O11" value="48.23" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.62" spread="10.40"/>
                    <measurement group_id="O2" value="39.40" spread="10.26"/>
                    <measurement group_id="O3" value="42.84" spread="12.53"/>
                    <measurement group_id="O4" value="43.84" spread="9.05"/>
                    <measurement group_id="O5" value="45.25" spread="11.64"/>
                    <measurement group_id="O6" value="43.56" spread="10.73"/>
                    <measurement group_id="O7" value="44.67" spread="10.31"/>
                    <measurement group_id="O8" value="46.35" spread="10.53"/>
                    <measurement group_id="O9" value="38.67" spread="12.38"/>
                    <measurement group_id="O10" value="45.18" spread="10.60"/>
                    <measurement group_id="O11" value="43.05" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.23" spread="11.08"/>
                    <measurement group_id="O2" value="34.30" spread="10.59"/>
                    <measurement group_id="O3" value="40.59" spread="13.86"/>
                    <measurement group_id="O4" value="37.94" spread="12.35"/>
                    <measurement group_id="O5" value="41.46" spread="12.40"/>
                    <measurement group_id="O6" value="40.15" spread="11.58"/>
                    <measurement group_id="O7" value="40.39" spread="11.88"/>
                    <measurement group_id="O8" value="42.31" spread="13.71"/>
                    <measurement group_id="O9" value="37.09" spread="16.56"/>
                    <measurement group_id="O10" value="42.27" spread="13.09"/>
                    <measurement group_id="O11" value="46.28" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.92" spread="11.10"/>
                    <measurement group_id="O2" value="38.74" spread="10.58"/>
                    <measurement group_id="O3" value="45.66" spread="12.59"/>
                    <measurement group_id="O4" value="44.59" spread="7.04"/>
                    <measurement group_id="O5" value="47.29" spread="13.62"/>
                    <measurement group_id="O6" value="43.89" spread="10.93"/>
                    <measurement group_id="O7" value="46.86" spread="11.73"/>
                    <measurement group_id="O8" value="47.24" spread="11.36"/>
                    <measurement group_id="O9" value="43.44" spread="12.84"/>
                    <measurement group_id="O10" value="45.63" spread="14.22"/>
                    <measurement group_id="O11" value="47.52" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.94" spread="8.41"/>
                    <measurement group_id="O2" value="36.79" spread="9.76"/>
                    <measurement group_id="O3" value="40.31" spread="9.95"/>
                    <measurement group_id="O4" value="39.74" spread="9.76"/>
                    <measurement group_id="O5" value="41.12" spread="9.22"/>
                    <measurement group_id="O6" value="40.85" spread="9.79"/>
                    <measurement group_id="O7" value="40.99" spread="9.14"/>
                    <measurement group_id="O8" value="42.81" spread="10.22"/>
                    <measurement group_id="O9" value="34.40" spread="10.57"/>
                    <measurement group_id="O10" value="42.09" spread="9.20"/>
                    <measurement group_id="O11" value="39.41" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.62" spread="12.04"/>
                    <measurement group_id="O2" value="39.10" spread="11.18"/>
                    <measurement group_id="O3" value="46.21" spread="13.26"/>
                    <measurement group_id="O4" value="44.52" spread="7.18"/>
                    <measurement group_id="O5" value="47.34" spread="13.41"/>
                    <measurement group_id="O6" value="45.03" spread="11.20"/>
                    <measurement group_id="O7" value="47.21" spread="11.71"/>
                    <measurement group_id="O8" value="48.03" spread="11.81"/>
                    <measurement group_id="O9" value="43.35" spread="13.89"/>
                    <measurement group_id="O10" value="47.08" spread="15.31"/>
                    <measurement group_id="O11" value="49.27" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET</title>
        <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
        <time_frame>Baseline, Week 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET</title>
          <description>SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="7.08"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.39" spread="9.60"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.57" spread="8.25"/>
                    <measurement group_id="O6" value="4.18" spread="11.13"/>
                    <measurement group_id="O7" value="5.96" spread="8.21"/>
                    <measurement group_id="O8" value="7.40" spread="9.15"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.24" spread="8.79"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="8.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.61" spread="11.45"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="2.68" spread="9.44"/>
                    <measurement group_id="O6" value="4.52" spread="11.62"/>
                    <measurement group_id="O7" value="5.20" spread="9.27"/>
                    <measurement group_id="O8" value="6.86" spread="9.69"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.01" spread="9.91"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" spread="8.12"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="8.80" spread="11.96"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="7.28" spread="10.29"/>
                    <measurement group_id="O6" value="8.74" spread="10.66"/>
                    <measurement group_id="O7" value="9.23" spread="9.48"/>
                    <measurement group_id="O8" value="10.54" spread="9.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.23" spread="8.98"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="7.04"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.84" spread="7.61"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.78" spread="8.81"/>
                    <measurement group_id="O6" value="2.73" spread="7.46"/>
                    <measurement group_id="O7" value="4.32" spread="8.59"/>
                    <measurement group_id="O8" value="4.97" spread="9.64"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.47" spread="10.32"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="8.99"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.29" spread="9.92"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.68" spread="9.86"/>
                    <measurement group_id="O6" value="2.29" spread="8.80"/>
                    <measurement group_id="O7" value="6.87" spread="8.76"/>
                    <measurement group_id="O8" value="5.22" spread="8.28"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.45" spread="11.66"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="10.54"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.99" spread="10.54"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.26" spread="9.93"/>
                    <measurement group_id="O6" value="3.49" spread="11.84"/>
                    <measurement group_id="O7" value="4.70" spread="10.33"/>
                    <measurement group_id="O8" value="5.84" spread="12.43"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.80" spread="9.70"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="10.65"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.69" spread="13.12"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="2.25" spread="11.23"/>
                    <measurement group_id="O6" value="2.73" spread="13.28"/>
                    <measurement group_id="O7" value="3.77" spread="13.04"/>
                    <measurement group_id="O8" value="5.33" spread="12.06"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.96" spread="12.04"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="9.27"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="4.63" spread="10.01"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.43" spread="10.19"/>
                    <measurement group_id="O6" value="0.04" spread="9.08"/>
                    <measurement group_id="O7" value="4.68" spread="8.73"/>
                    <measurement group_id="O8" value="5.59" spread="9.87"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.88" spread="9.76"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="6.38"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.16" spread="8.82"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="5.30" spread="8.03"/>
                    <measurement group_id="O6" value="6.32" spread="8.72"/>
                    <measurement group_id="O7" value="6.77" spread="7.29"/>
                    <measurement group_id="O8" value="7.98" spread="7.95"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.71" spread="7.43"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="9.47"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="3.94" spread="10.38"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="2.72" spread="9.57"/>
                    <measurement group_id="O6" value="0.28" spread="10.13"/>
                    <measurement group_id="O7" value="3.81" spread="9.58"/>
                    <measurement group_id="O8" value="4.18" spread="10.04"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-1.40" spread="9.18"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="8.32"/>
                    <measurement group_id="O2" value="2.63" spread="9.94"/>
                    <measurement group_id="O3" value="5.45" spread="8.57"/>
                    <measurement group_id="O4" value="4.37" spread="8.35"/>
                    <measurement group_id="O5" value="7.77" spread="9.41"/>
                    <measurement group_id="O6" value="6.41" spread="11.62"/>
                    <measurement group_id="O7" value="6.63" spread="10.30"/>
                    <measurement group_id="O8" value="8.81" spread="10.48"/>
                    <measurement group_id="O9" value="6.49" spread="8.15"/>
                    <measurement group_id="O10" value="3.74" spread="9.56"/>
                    <measurement group_id="O11" value="4.21" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="8.34"/>
                    <measurement group_id="O2" value="1.47" spread="7.72"/>
                    <measurement group_id="O3" value="5.07" spread="11.00"/>
                    <measurement group_id="O4" value="4.52" spread="6.77"/>
                    <measurement group_id="O5" value="6.01" spread="10.23"/>
                    <measurement group_id="O6" value="5.56" spread="9.76"/>
                    <measurement group_id="O7" value="6.61" spread="9.33"/>
                    <measurement group_id="O8" value="7.25" spread="11.27"/>
                    <measurement group_id="O9" value="5.51" spread="10.50"/>
                    <measurement group_id="O10" value="5.85" spread="11.43"/>
                    <measurement group_id="O11" value="4.75" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="9.91"/>
                    <measurement group_id="O2" value="3.85" spread="8.92"/>
                    <measurement group_id="O3" value="10.16" spread="9.54"/>
                    <measurement group_id="O4" value="9.75" spread="7.27"/>
                    <measurement group_id="O5" value="10.09" spread="10.44"/>
                    <measurement group_id="O6" value="9.21" spread="10.31"/>
                    <measurement group_id="O7" value="10.44" spread="10.51"/>
                    <measurement group_id="O8" value="11.86" spread="10.67"/>
                    <measurement group_id="O9" value="10.67" spread="12.01"/>
                    <measurement group_id="O10" value="5.92" spread="10.51"/>
                    <measurement group_id="O11" value="7.73" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="7.70"/>
                    <measurement group_id="O2" value="3.58" spread="6.97"/>
                    <measurement group_id="O3" value="5.92" spread="7.09"/>
                    <measurement group_id="O4" value="4.11" spread="9.07"/>
                    <measurement group_id="O5" value="6.34" spread="7.85"/>
                    <measurement group_id="O6" value="4.68" spread="8.77"/>
                    <measurement group_id="O7" value="5.41" spread="7.88"/>
                    <measurement group_id="O8" value="6.43" spread="8.93"/>
                    <measurement group_id="O9" value="5.92" spread="9.84"/>
                    <measurement group_id="O10" value="4.20" spread="12.05"/>
                    <measurement group_id="O11" value="4.04" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" spread="9.94"/>
                    <measurement group_id="O2" value="1.56" spread="10.79"/>
                    <measurement group_id="O3" value="5.82" spread="9.30"/>
                    <measurement group_id="O4" value="5.04" spread="10.16"/>
                    <measurement group_id="O5" value="6.64" spread="9.03"/>
                    <measurement group_id="O6" value="3.52" spread="9.27"/>
                    <measurement group_id="O7" value="8.53" spread="9.99"/>
                    <measurement group_id="O8" value="7.95" spread="11.17"/>
                    <measurement group_id="O9" value="6.76" spread="11.52"/>
                    <measurement group_id="O10" value="2.08" spread="13.86"/>
                    <measurement group_id="O11" value="6.06" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="9.36"/>
                    <measurement group_id="O2" value="3.27" spread="12.31"/>
                    <measurement group_id="O3" value="4.09" spread="11.10"/>
                    <measurement group_id="O4" value="5.87" spread="10.31"/>
                    <measurement group_id="O5" value="7.54" spread="10.36"/>
                    <measurement group_id="O6" value="4.16" spread="11.99"/>
                    <measurement group_id="O7" value="4.91" spread="10.27"/>
                    <measurement group_id="O8" value="6.79" spread="11.86"/>
                    <measurement group_id="O9" value="3.64" spread="11.71"/>
                    <measurement group_id="O10" value="3.33" spread="12.73"/>
                    <measurement group_id="O11" value="3.85" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="11.30"/>
                    <measurement group_id="O2" value="2.33" spread="12.82"/>
                    <measurement group_id="O3" value="5.48" spread="16.05"/>
                    <measurement group_id="O4" value="-0.30" spread="13.69"/>
                    <measurement group_id="O5" value="4.24" spread="11.81"/>
                    <measurement group_id="O6" value="4.01" spread="13.30"/>
                    <measurement group_id="O7" value="5.18" spread="11.73"/>
                    <measurement group_id="O8" value="5.57" spread="14.61"/>
                    <measurement group_id="O9" value="2.27" spread="16.86"/>
                    <measurement group_id="O10" value="0.97" spread="13.70"/>
                    <measurement group_id="O11" value="2.29" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="12.82"/>
                    <measurement group_id="O2" value="1.83" spread="8.73"/>
                    <measurement group_id="O3" value="4.99" spread="11.52"/>
                    <measurement group_id="O4" value="4.98" spread="11.27"/>
                    <measurement group_id="O5" value="5.43" spread="11.92"/>
                    <measurement group_id="O6" value="0.36" spread="10.48"/>
                    <measurement group_id="O7" value="5.44" spread="8.23"/>
                    <measurement group_id="O8" value="5.31" spread="12.73"/>
                    <measurement group_id="O9" value="6.57" spread="12.84"/>
                    <measurement group_id="O10" value="0.70" spread="9.97"/>
                    <measurement group_id="O11" value="0.99" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" spread="7.90"/>
                    <measurement group_id="O2" value="2.91" spread="7.31"/>
                    <measurement group_id="O3" value="6.78" spread="7.17"/>
                    <measurement group_id="O4" value="6.62" spread="5.93"/>
                    <measurement group_id="O5" value="8.31" spread="8.48"/>
                    <measurement group_id="O6" value="7.99" spread="9.21"/>
                    <measurement group_id="O7" value="7.81" spread="8.84"/>
                    <measurement group_id="O8" value="9.59" spread="8.67"/>
                    <measurement group_id="O9" value="7.83" spread="7.89"/>
                    <measurement group_id="O10" value="6.26" spread="9.97"/>
                    <measurement group_id="O11" value="6.40" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="12.35"/>
                    <measurement group_id="O2" value="1.93" spread="11.99"/>
                    <measurement group_id="O3" value="4.31" spread="13.10"/>
                    <measurement group_id="O4" value="2.48" spread="11.80"/>
                    <measurement group_id="O5" value="4.46" spread="10.55"/>
                    <measurement group_id="O6" value="0.73" spread="10.85"/>
                    <measurement group_id="O7" value="4.78" spread="9.04"/>
                    <measurement group_id="O8" value="4.52" spread="12.52"/>
                    <measurement group_id="O9" value="3.44" spread="14.10"/>
                    <measurement group_id="O10" value="-0.07" spread="12.42"/>
                    <measurement group_id="O11" value="1.57" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, Week 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.29"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.46" spread="0.33"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.50" spread="0.30"/>
                    <measurement group_id="O6" value="0.48" spread="0.28"/>
                    <measurement group_id="O7" value="0.46" spread="0.31"/>
                    <measurement group_id="O8" value="0.49" spread="0.28"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.49" spread="0.33"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.20"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.59" spread="0.30"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.62" spread="0.26"/>
                    <measurement group_id="O6" value="0.65" spread="0.23"/>
                    <measurement group_id="O7" value="0.63" spread="0.27"/>
                    <measurement group_id="O8" value="0.64" spread="0.25"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.55" spread="0.31"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.23"/>
                    <measurement group_id="O2" value="0.46" spread="0.42"/>
                    <measurement group_id="O3" value="0.67" spread="0.26"/>
                    <measurement group_id="O4" value="0.64" spread="0.25"/>
                    <measurement group_id="O5" value="0.70" spread="0.23"/>
                    <measurement group_id="O6" value="0.68" spread="0.23"/>
                    <measurement group_id="O7" value="0.65" spread="0.25"/>
                    <measurement group_id="O8" value="0.71" spread="0.27"/>
                    <measurement group_id="O9" value="0.56" spread="0.32"/>
                    <measurement group_id="O10" value="0.65" spread="0.22"/>
                    <measurement group_id="O11" value="0.58" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, Week 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="61"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.26"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.16" spread="0.37"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.11" spread="0.32"/>
                    <measurement group_id="O6" value="0.17" spread="0.27"/>
                    <measurement group_id="O7" value="0.18" spread="0.29"/>
                    <measurement group_id="O8" value="0.16" spread="0.29"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.05" spread="0.35"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.30"/>
                    <measurement group_id="O2" value="0.00" spread="0.30"/>
                    <measurement group_id="O3" value="0.23" spread="0.33"/>
                    <measurement group_id="O4" value="0.23" spread="0.37"/>
                    <measurement group_id="O5" value="0.19" spread="0.30"/>
                    <measurement group_id="O6" value="0.20" spread="0.31"/>
                    <measurement group_id="O7" value="0.18" spread="0.29"/>
                    <measurement group_id="O8" value="0.17" spread="0.32"/>
                    <measurement group_id="O9" value="0.20" spread="0.45"/>
                    <measurement group_id="O10" value="0.13" spread="0.30"/>
                    <measurement group_id="O11" value="0.03" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcome Study- Sleep Scale (MOS-SS)</title>
        <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
        <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcome Study- Sleep Scale (MOS-SS)</title>
          <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="80"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.62" spread="18.87"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="44.46" spread="21.58"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="38.12" spread="18.93"/>
                    <measurement group_id="O6" value="36.94" spread="18.49"/>
                    <measurement group_id="O7" value="40.90" spread="22.41"/>
                    <measurement group_id="O8" value="38.46" spread="21.21"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="38.26" spread="19.58"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.94" spread="18.04"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="45.65" spread="20.86"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="40.22" spread="19.00"/>
                    <measurement group_id="O6" value="39.05" spread="18.56"/>
                    <measurement group_id="O7" value="42.87" spread="20.62"/>
                    <measurement group_id="O8" value="40.49" spread="21.33"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="38.86" spread="19.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.14" spread="25.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="43.82" spread="26.99"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="46.20" spread="27.95"/>
                    <measurement group_id="O6" value="50.27" spread="26.84"/>
                    <measurement group_id="O7" value="49.19" spread="28.13"/>
                    <measurement group_id="O8" value="51.00" spread="30.55"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="51.45" spread="28.45"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="24.55"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="22.94" spread="24.50"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="17.75" spread="22.82"/>
                    <measurement group_id="O6" value="17.30" spread="22.29"/>
                    <measurement group_id="O7" value="21.87" spread="25.93"/>
                    <measurement group_id="O8" value="20.50" spread="27.55"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="22.61" spread="25.88"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.43" spread="23.13"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="49.10" spread="27.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="42.61" spread="25.40"/>
                    <measurement group_id="O6" value="41.17" spread="25.36"/>
                    <measurement group_id="O7" value="48.37" spread="25.66"/>
                    <measurement group_id="O8" value="44.42" spread="27.37"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="40.34" spread="26.04"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.44" spread="0.50"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.46" spread="0.50"/>
                    <measurement group_id="O6" value="0.45" spread="0.50"/>
                    <measurement group_id="O7" value="0.47" spread="0.50"/>
                    <measurement group_id="O8" value="0.50" spread="0.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.52" spread="0.50"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="1.73"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="6.72" spread="1.60"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="7.32" spread="7.65"/>
                    <measurement group_id="O6" value="7.28" spread="3.54"/>
                    <measurement group_id="O7" value="6.64" spread="1.61"/>
                    <measurement group_id="O8" value="6.90" spread="1.52"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="6.71" spread="1.47"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.59" spread="30.76"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.29" spread="32.07"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="44.51" spread="33.16"/>
                    <measurement group_id="O6" value="39.73" spread="33.19"/>
                    <measurement group_id="O7" value="36.00" spread="34.01"/>
                    <measurement group_id="O8" value="35.25" spread="32.49"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.94" spread="33.88"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14" spread="20.30"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="38.63" spread="23.51"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="32.86" spread="19.17"/>
                    <measurement group_id="O6" value="34.50" spread="19.03"/>
                    <measurement group_id="O7" value="35.91" spread="22.08"/>
                    <measurement group_id="O8" value="35.04" spread="22.93"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="33.04" spread="20.69"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.65" spread="21.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="37.89" spread="22.17"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="34.22" spread="21.10"/>
                    <measurement group_id="O6" value="35.25" spread="19.10"/>
                    <measurement group_id="O7" value="32.97" spread="21.75"/>
                    <measurement group_id="O8" value="35.78" spread="20.40"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.34" spread="20.21"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.04" spread="19.70"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="37.88" spread="21.48"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="34.74" spread="20.11"/>
                    <measurement group_id="O6" value="35.65" spread="19.37"/>
                    <measurement group_id="O7" value="35.27" spread="20.56"/>
                    <measurement group_id="O8" value="36.22" spread="19.65"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.67" spread="18.79"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.15" spread="27.62"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="49.56" spread="28.31"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="53.24" spread="31.64"/>
                    <measurement group_id="O6" value="53.42" spread="25.40"/>
                    <measurement group_id="O7" value="57.53" spread="28.81"/>
                    <measurement group_id="O8" value="50.51" spread="27.68"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="54.24" spread="29.87"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.29" spread="25.04"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="17.65" spread="22.27"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="17.94" spread="22.70"/>
                    <measurement group_id="O6" value="22.74" spread="24.11"/>
                    <measurement group_id="O7" value="15.34" spread="21.74"/>
                    <measurement group_id="O8" value="20.25" spread="26.11"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="17.88" spread="23.57"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.15" spread="22.53"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="39.21" spread="27.05"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="35.00" spread="23.80"/>
                    <measurement group_id="O6" value="34.93" spread="24.83"/>
                    <measurement group_id="O7" value="38.73" spread="26.23"/>
                    <measurement group_id="O8" value="35.87" spread="24.33"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="37.33" spread="25.29"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.43" spread="0.50"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.53" spread="0.50"/>
                    <measurement group_id="O6" value="0.52" spread="0.50"/>
                    <measurement group_id="O7" value="0.52" spread="0.50"/>
                    <measurement group_id="O8" value="0.44" spread="0.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.59" spread="0.50"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.75" spread="1.73"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="6.76" spread="1.40"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.72" spread="1.26"/>
                    <measurement group_id="O6" value="7.05" spread="1.30"/>
                    <measurement group_id="O7" value="7.10" spread="1.70"/>
                    <measurement group_id="O8" value="6.78" spread="1.65"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="7.08" spread="1.53"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.94" spread="29.88"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.59" spread="32.94"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="37.01" spread="31.38"/>
                    <measurement group_id="O6" value="35.62" spread="33.21"/>
                    <measurement group_id="O7" value="30.96" spread="33.01"/>
                    <measurement group_id="O8" value="30.63" spread="30.18"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.76" spread="35.17"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.34" spread="21.03"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="33.63" spread="24.25"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="31.08" spread="21.66"/>
                    <measurement group_id="O6" value="33.79" spread="20.97"/>
                    <measurement group_id="O7" value="32.69" spread="21.26"/>
                    <measurement group_id="O8" value="31.73" spread="22.32"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="30.51" spread="20.56"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.05" spread="16.56"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="33.62" spread="22.04"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="33.39" spread="20.64"/>
                    <measurement group_id="O6" value="34.92" spread="18.85"/>
                    <measurement group_id="O7" value="35.00" spread="19.41"/>
                    <measurement group_id="O8" value="32.81" spread="21.22"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.26" spread="22.07"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.78" spread="16.37"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="34.23" spread="20.63"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="33.61" spread="19.83"/>
                    <measurement group_id="O6" value="35.26" spread="19.48"/>
                    <measurement group_id="O7" value="36.33" spread="19.86"/>
                    <measurement group_id="O8" value="33.44" spread="21.57"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="34.50" spread="20.96"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.35" spread="24.69"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="54.92" spread="32.24"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="53.17" spread="29.99"/>
                    <measurement group_id="O6" value="54.00" spread="26.74"/>
                    <measurement group_id="O7" value="56.09" spread="28.21"/>
                    <measurement group_id="O8" value="58.43" spread="27.59"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="54.59" spread="27.72"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.16" spread="22.52"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="13.90" spread="19.39"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="20.32" spread="27.24"/>
                    <measurement group_id="O6" value="20.00" spread="23.72"/>
                    <measurement group_id="O7" value="18.75" spread="22.50"/>
                    <measurement group_id="O8" value="21.43" spread="26.00"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="20.98" spread="28.85"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.94" spread="20.00"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.66" spread="26.03"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="32.52" spread="23.96"/>
                    <measurement group_id="O6" value="34.27" spread="25.00"/>
                    <measurement group_id="O7" value="39.16" spread="25.16"/>
                    <measurement group_id="O8" value="34.18" spread="27.10"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.41" spread="26.22"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.53" spread="0.50"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.48" spread="0.50"/>
                    <measurement group_id="O6" value="0.54" spread="0.50"/>
                    <measurement group_id="O7" value="0.45" spread="0.50"/>
                    <measurement group_id="O8" value="0.51" spread="0.50"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.48" spread="0.50"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="1.41"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="7.05" spread="1.53"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.71" spread="1.49"/>
                    <measurement group_id="O6" value="6.85" spread="1.33"/>
                    <measurement group_id="O7" value="6.98" spread="1.74"/>
                    <measurement group_id="O8" value="7.60" spread="5.37"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="8.10" spread="9.47"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.18" spread="26.97"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="34.92" spread="32.71"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="41.59" spread="32.19"/>
                    <measurement group_id="O6" value="35.69" spread="32.11"/>
                    <measurement group_id="O7" value="34.69" spread="32.71"/>
                    <measurement group_id="O8" value="33.43" spread="29.63"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="30.82" spread="31.53"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.82" spread="18.61"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="32.20" spread="21.52"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="31.01" spread="23.10"/>
                    <measurement group_id="O6" value="34.36" spread="23.22"/>
                    <measurement group_id="O7" value="32.29" spread="20.62"/>
                    <measurement group_id="O8" value="30.57" spread="25.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="28.96" spread="18.77"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.17" spread="17.35"/>
                    <measurement group_id="O2" value="43.67" spread="20.23"/>
                    <measurement group_id="O3" value="30.68" spread="21.02"/>
                    <measurement group_id="O4" value="38.21" spread="17.46"/>
                    <measurement group_id="O5" value="32.55" spread="22.35"/>
                    <measurement group_id="O6" value="32.50" spread="18.22"/>
                    <measurement group_id="O7" value="29.89" spread="18.91"/>
                    <measurement group_id="O8" value="25.45" spread="17.75"/>
                    <measurement group_id="O9" value="44.44" spread="27.09"/>
                    <measurement group_id="O10" value="29.51" spread="19.04"/>
                    <measurement group_id="O11" value="32.55" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.64" spread="16.38"/>
                    <measurement group_id="O2" value="42.86" spread="19.06"/>
                    <measurement group_id="O3" value="31.46" spread="19.54"/>
                    <measurement group_id="O4" value="38.80" spread="18.07"/>
                    <measurement group_id="O5" value="32.18" spread="21.24"/>
                    <measurement group_id="O6" value="32.95" spread="18.88"/>
                    <measurement group_id="O7" value="31.18" spread="19.77"/>
                    <measurement group_id="O8" value="26.76" spread="17.75"/>
                    <measurement group_id="O9" value="47.27" spread="27.08"/>
                    <measurement group_id="O10" value="30.41" spread="18.52"/>
                    <measurement group_id="O11" value="33.04" spread="21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" spread="25.74"/>
                    <measurement group_id="O2" value="39.50" spread="27.81"/>
                    <measurement group_id="O3" value="58.41" spread="28.69"/>
                    <measurement group_id="O4" value="46.15" spread="18.05"/>
                    <measurement group_id="O5" value="55.64" spread="31.61"/>
                    <measurement group_id="O6" value="57.34" spread="26.32"/>
                    <measurement group_id="O7" value="57.46" spread="26.43"/>
                    <measurement group_id="O8" value="66.92" spread="28.60"/>
                    <measurement group_id="O9" value="44.17" spread="34.50"/>
                    <measurement group_id="O10" value="57.65" spread="27.64"/>
                    <measurement group_id="O11" value="55.29" spread="33.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="17.66"/>
                    <measurement group_id="O2" value="20.00" spread="26.75"/>
                    <measurement group_id="O3" value="12.73" spread="18.85"/>
                    <measurement group_id="O4" value="18.46" spread="17.25"/>
                    <measurement group_id="O5" value="14.18" spread="20.61"/>
                    <measurement group_id="O6" value="17.19" spread="23.33"/>
                    <measurement group_id="O7" value="11.53" spread="19.72"/>
                    <measurement group_id="O8" value="11.15" spread="18.33"/>
                    <measurement group_id="O9" value="25.00" spread="32.05"/>
                    <measurement group_id="O10" value="13.53" spread="15.35"/>
                    <measurement group_id="O11" value="14.12" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.31" spread="19.05"/>
                    <measurement group_id="O2" value="40.19" spread="21.76"/>
                    <measurement group_id="O3" value="30.80" spread="24.04"/>
                    <measurement group_id="O4" value="38.08" spread="28.62"/>
                    <measurement group_id="O5" value="32.77" spread="25.76"/>
                    <measurement group_id="O6" value="32.73" spread="26.78"/>
                    <measurement group_id="O7" value="32.61" spread="26.23"/>
                    <measurement group_id="O8" value="28.49" spread="23.70"/>
                    <measurement group_id="O9" value="52.19" spread="29.21"/>
                    <measurement group_id="O10" value="30.33" spread="24.00"/>
                    <measurement group_id="O11" value="36.40" spread="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.51"/>
                    <measurement group_id="O2" value="0.50" spread="0.51"/>
                    <measurement group_id="O3" value="0.55" spread="0.50"/>
                    <measurement group_id="O4" value="0.38" spread="0.51"/>
                    <measurement group_id="O5" value="0.45" spread="0.50"/>
                    <measurement group_id="O6" value="0.55" spread="0.50"/>
                    <measurement group_id="O7" value="0.45" spread="0.50"/>
                    <measurement group_id="O8" value="0.57" spread="0.50"/>
                    <measurement group_id="O9" value="0.33" spread="0.49"/>
                    <measurement group_id="O10" value="0.58" spread="0.50"/>
                    <measurement group_id="O11" value="0.41" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="1.44"/>
                    <measurement group_id="O2" value="6.80" spread="1.40"/>
                    <measurement group_id="O3" value="7.25" spread="1.31"/>
                    <measurement group_id="O4" value="6.69" spread="1.65"/>
                    <measurement group_id="O5" value="7.93" spread="7.26"/>
                    <measurement group_id="O6" value="6.94" spread="1.23"/>
                    <measurement group_id="O7" value="7.05" spread="1.85"/>
                    <measurement group_id="O8" value="7.12" spread="1.20"/>
                    <measurement group_id="O9" value="9.42" spread="12.87"/>
                    <measurement group_id="O10" value="7.43" spread="1.09"/>
                    <measurement group_id="O11" value="6.41" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.50" spread="23.70"/>
                    <measurement group_id="O2" value="38.00" spread="32.38"/>
                    <measurement group_id="O3" value="35.00" spread="31.73"/>
                    <measurement group_id="O4" value="44.62" spread="32.82"/>
                    <measurement group_id="O5" value="37.41" spread="32.05"/>
                    <measurement group_id="O6" value="38.13" spread="33.37"/>
                    <measurement group_id="O7" value="35.25" spread="30.25"/>
                    <measurement group_id="O8" value="38.46" spread="32.62"/>
                    <measurement group_id="O9" value="35.00" spread="28.44"/>
                    <measurement group_id="O10" value="27.06" spread="32.62"/>
                    <measurement group_id="O11" value="34.12" spread="33.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.50" spread="19.33"/>
                    <measurement group_id="O2" value="40.67" spread="20.85"/>
                    <measurement group_id="O3" value="34.39" spread="25.39"/>
                    <measurement group_id="O4" value="31.79" spread="18.49"/>
                    <measurement group_id="O5" value="29.94" spread="20.68"/>
                    <measurement group_id="O6" value="32.40" spread="24.05"/>
                    <measurement group_id="O7" value="28.70" spread="19.93"/>
                    <measurement group_id="O8" value="26.03" spread="21.42"/>
                    <measurement group_id="O9" value="33.89" spread="25.34"/>
                    <measurement group_id="O10" value="27.06" spread="17.67"/>
                    <measurement group_id="O11" value="23.14" spread="18.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET</title>
        <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range*100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
        <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET</title>
          <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range*100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="72"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="11.35"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-6.57" spread="15.20"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-3.43" spread="16.51"/>
                    <measurement group_id="O6" value="-2.05" spread="14.11"/>
                    <measurement group_id="O7" value="-7.45" spread="11.74"/>
                    <measurement group_id="O8" value="-2.36" spread="17.85"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-4.29" spread="13.12"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="10.26"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-7.76" spread="14.28"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-4.93" spread="14.92"/>
                    <measurement group_id="O6" value="-3.75" spread="12.36"/>
                    <measurement group_id="O7" value="-7.06" spread="10.93"/>
                    <measurement group_id="O8" value="-4.07" spread="15.98"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-3.30" spread="12.13"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="22.72"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.74" spread="21.04"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="6.76" spread="25.06"/>
                    <measurement group_id="O6" value="3.70" spread="26.11"/>
                    <measurement group_id="O7" value="7.64" spread="16.74"/>
                    <measurement group_id="O8" value="-0.51" spread="28.68"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="3.18" spread="19.70"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="19.70"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-5.29" spread="20.62"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.29" spread="25.27"/>
                    <measurement group_id="O6" value="5.48" spread="21.15"/>
                    <measurement group_id="O7" value="-6.03" spread="21.78"/>
                    <measurement group_id="O8" value="0.00" spread="20.51"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-5.76" spread="25.24"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.64" spread="13.23"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-9.89" spread="17.97"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-6.82" spread="18.04"/>
                    <measurement group_id="O6" value="-6.73" spread="15.61"/>
                    <measurement group_id="O7" value="-8.77" spread="15.11"/>
                    <measurement group_id="O8" value="-7.85" spread="20.80"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.81" spread="17.05"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.52"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.01" spread="0.47"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.04" spread="0.44"/>
                    <measurement group_id="O6" value="0.07" spread="0.56"/>
                    <measurement group_id="O7" value="0.04" spread="0.54"/>
                    <measurement group_id="O8" value="-0.05" spread="0.53"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.08" spread="0.36"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.21"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.03" spread="1.07"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.69" spread="7.75"/>
                    <measurement group_id="O6" value="-0.21" spread="3.75"/>
                    <measurement group_id="O7" value="0.41" spread="1.21"/>
                    <measurement group_id="O8" value="-0.09" spread="1.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.36" spread="0.99"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="22.99"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.29" spread="22.26"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-7.46" spread="21.97"/>
                    <measurement group_id="O6" value="-4.66" spread="23.46"/>
                    <measurement group_id="O7" value="-4.11" spread="21.33"/>
                    <measurement group_id="O8" value="-4.05" spread="23.62"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.91" spread="23.91"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="18.47"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-5.00" spread="18.33"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.37" spread="18.05"/>
                    <measurement group_id="O6" value="-0.73" spread="16.20"/>
                    <measurement group_id="O7" value="-2.74" spread="15.79"/>
                    <measurement group_id="O8" value="-3.03" spread="17.76"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.22" spread="18.47"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" spread="12.21"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-10.51" spread="20.72"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-3.97" spread="18.57"/>
                    <measurement group_id="O6" value="-2.00" spread="19.98"/>
                    <measurement group_id="O7" value="-5.19" spread="19.19"/>
                    <measurement group_id="O8" value="-4.62" spread="17.24"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.95" spread="18.20"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.27" spread="11.71"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-11.21" spread="18.59"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-5.59" spread="18.71"/>
                    <measurement group_id="O6" value="-3.64" spread="18.32"/>
                    <measurement group_id="O7" value="-5.63" spread="17.18"/>
                    <measurement group_id="O8" value="-6.42" spread="15.31"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-3.03" spread="17.70"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="22.39"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="11.19" spread="27.55"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="5.87" spread="27.51"/>
                    <measurement group_id="O6" value="4.77" spread="29.32"/>
                    <measurement group_id="O7" value="6.51" spread="25.15"/>
                    <measurement group_id="O8" value="6.57" spread="32.16"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="0.82" spread="23.47"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.87" spread="24.52"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-7.46" spread="24.89"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.81" spread="28.70"/>
                    <measurement group_id="O6" value="2.46" spread="26.10"/>
                    <measurement group_id="O7" value="-2.81" spread="23.87"/>
                    <measurement group_id="O8" value="1.43" spread="24.15"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-1.97" spread="25.22"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.74" spread="16.98"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-13.43" spread="22.93"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-9.25" spread="23.07"/>
                    <measurement group_id="O6" value="-6.73" spread="22.54"/>
                    <measurement group_id="O7" value="-8.22" spread="20.59"/>
                    <measurement group_id="O8" value="-8.45" spread="18.59"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-2.97" spread="21.46"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.54"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.07" spread="0.61"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="0.03" spread="0.64"/>
                    <measurement group_id="O6" value="0.08" spread="0.62"/>
                    <measurement group_id="O7" value="-0.05" spread="0.57"/>
                    <measurement group_id="O8" value="0.01" spread="0.58"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-0.08" spread="0.53"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="1.43"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="0.40" spread="1.32"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-0.73" spread="8.24"/>
                    <measurement group_id="O6" value="-0.42" spread="3.80"/>
                    <measurement group_id="O7" value="0.28" spread="1.52"/>
                    <measurement group_id="O8" value="0.74" spread="5.57"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.33" spread="9.25"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="22.20"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-0.34" spread="27.67"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-2.54" spread="28.85"/>
                    <measurement group_id="O6" value="-2.15" spread="26.25"/>
                    <measurement group_id="O7" value="1.56" spread="24.25"/>
                    <measurement group_id="O8" value="-1.14" spread="22.04"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-3.28" spread="19.38"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.56" spread="18.60"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="-6.33" spread="19.08"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="-1.06" spread="19.20"/>
                    <measurement group_id="O6" value="1.54" spread="23.06"/>
                    <measurement group_id="O7" value="-2.81" spread="20.33"/>
                    <measurement group_id="O8" value="-4.90" spread="20.72"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="-4.37" spread="21.56"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.25" spread="15.47"/>
                    <measurement group_id="O2" value="-0.50" spread="15.83"/>
                    <measurement group_id="O3" value="-11.97" spread="19.23"/>
                    <measurement group_id="O4" value="-6.92" spread="18.13"/>
                    <measurement group_id="O5" value="-4.12" spread="20.03"/>
                    <measurement group_id="O6" value="-3.33" spread="16.38"/>
                    <measurement group_id="O7" value="-8.62" spread="18.34"/>
                    <measurement group_id="O8" value="-7.82" spread="18.23"/>
                    <measurement group_id="O9" value="-3.33" spread="20.84"/>
                    <measurement group_id="O10" value="-6.27" spread="19.96"/>
                    <measurement group_id="O11" value="-2.16" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.18" spread="14.38"/>
                    <measurement group_id="O2" value="-2.81" spread="14.39"/>
                    <measurement group_id="O3" value="-12.16" spread="17.87"/>
                    <measurement group_id="O4" value="-8.50" spread="16.00"/>
                    <measurement group_id="O5" value="-6.04" spread="19.83"/>
                    <measurement group_id="O6" value="-4.83" spread="16.17"/>
                    <measurement group_id="O7" value="-9.82" spread="16.06"/>
                    <measurement group_id="O8" value="-9.24" spread="18.00"/>
                    <measurement group_id="O9" value="-3.38" spread="18.83"/>
                    <measurement group_id="O10" value="-6.01" spread="18.67"/>
                    <measurement group_id="O11" value="-1.96" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="26.36"/>
                    <measurement group_id="O2" value="-6.00" spread="25.42"/>
                    <measurement group_id="O3" value="11.59" spread="24.30"/>
                    <measurement group_id="O4" value="9.23" spread="23.97"/>
                    <measurement group_id="O5" value="8.00" spread="28.11"/>
                    <measurement group_id="O6" value="6.72" spread="29.33"/>
                    <measurement group_id="O7" value="5.52" spread="26.70"/>
                    <measurement group_id="O8" value="11.92" spread="32.36"/>
                    <measurement group_id="O9" value="-1.67" spread="39.73"/>
                    <measurement group_id="O10" value="-1.18" spread="29.72"/>
                    <measurement group_id="O11" value="8.82" spread="19.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="20.20"/>
                    <measurement group_id="O2" value="-7.00" spread="29.22"/>
                    <measurement group_id="O3" value="-11.36" spread="27.42"/>
                    <measurement group_id="O4" value="-1.54" spread="26.41"/>
                    <measurement group_id="O5" value="-3.27" spread="24.27"/>
                    <measurement group_id="O6" value="0.63" spread="24.94"/>
                    <measurement group_id="O7" value="-10.17" spread="25.56"/>
                    <measurement group_id="O8" value="-5.38" spread="19.45"/>
                    <measurement group_id="O9" value="-6.67" spread="21.46"/>
                    <measurement group_id="O10" value="-11.18" spread="21.57"/>
                    <measurement group_id="O11" value="3.53" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.66" spread="18.64"/>
                    <measurement group_id="O2" value="-6.31" spread="17.76"/>
                    <measurement group_id="O3" value="-15.88" spread="24.63"/>
                    <measurement group_id="O4" value="-13.75" spread="21.22"/>
                    <measurement group_id="O5" value="-6.59" spread="25.51"/>
                    <measurement group_id="O6" value="-6.64" spread="22.53"/>
                    <measurement group_id="O7" value="-13.98" spread="18.70"/>
                    <measurement group_id="O8" value="-8.94" spread="22.39"/>
                    <measurement group_id="O9" value="-7.19" spread="18.41"/>
                    <measurement group_id="O10" value="-7.06" spread="23.78"/>
                    <measurement group_id="O11" value="-1.18" spread="27.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.51"/>
                    <measurement group_id="O2" value="0.00" spread="0.65"/>
                    <measurement group_id="O3" value="0.07" spread="0.62"/>
                    <measurement group_id="O4" value="-0.08" spread="0.64"/>
                    <measurement group_id="O5" value="0.02" spread="0.62"/>
                    <measurement group_id="O6" value="0.08" spread="0.65"/>
                    <measurement group_id="O7" value="-0.05" spread="0.53"/>
                    <measurement group_id="O8" value="0.02" spread="0.54"/>
                    <measurement group_id="O9" value="0.00" spread="0.74"/>
                    <measurement group_id="O10" value="-0.08" spread="0.60"/>
                    <measurement group_id="O11" value="-0.06" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.26"/>
                    <measurement group_id="O2" value="0.00" spread="1.65"/>
                    <measurement group_id="O3" value="0.35" spread="1.56"/>
                    <measurement group_id="O4" value="0.38" spread="1.66"/>
                    <measurement group_id="O5" value="0.33" spread="2.13"/>
                    <measurement group_id="O6" value="-0.42" spread="3.97"/>
                    <measurement group_id="O7" value="0.31" spread="1.44"/>
                    <measurement group_id="O8" value="0.08" spread="1.04"/>
                    <measurement group_id="O9" value="3.36" spread="13.89"/>
                    <measurement group_id="O10" value="0.29" spread="1.45"/>
                    <measurement group_id="O11" value="0.24" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="25.17"/>
                    <measurement group_id="O2" value="-1.05" spread="23.55"/>
                    <measurement group_id="O3" value="2.73" spread="28.48"/>
                    <measurement group_id="O4" value="6.15" spread="18.95"/>
                    <measurement group_id="O5" value="-7.04" spread="24.92"/>
                    <measurement group_id="O6" value="0.31" spread="28.84"/>
                    <measurement group_id="O7" value="2.37" spread="22.92"/>
                    <measurement group_id="O8" value="1.54" spread="28.79"/>
                    <measurement group_id="O9" value="5.00" spread="30.90"/>
                    <measurement group_id="O10" value="-6.47" spread="26.84"/>
                    <measurement group_id="O11" value="-1.18" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="21.94"/>
                    <measurement group_id="O2" value="0.67" spread="18.34"/>
                    <measurement group_id="O3" value="-2.58" spread="20.29"/>
                    <measurement group_id="O4" value="-4.10" spread="15.04"/>
                    <measurement group_id="O5" value="-2.18" spread="21.08"/>
                    <measurement group_id="O6" value="-1.04" spread="20.03"/>
                    <measurement group_id="O7" value="-6.55" spread="20.02"/>
                    <measurement group_id="O8" value="-6.80" spread="21.19"/>
                    <measurement group_id="O9" value="-4.24" spread="18.68"/>
                    <measurement group_id="O10" value="-7.06" spread="17.36"/>
                    <measurement group_id="O11" value="-2.35" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale</title>
        <description>FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale</title>
          <description>FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="75"/>
                <count group_id="O8" value="79"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="69"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=70,0,68,0,71,73,75,79,0,69,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.17" spread="10.50"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="29.92" spread="11.98"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="28.76" spread="10.42"/>
                    <measurement group_id="O6" value="30.06" spread="10.85"/>
                    <measurement group_id="O7" value="29.48" spread="10.19"/>
                    <measurement group_id="O8" value="29.76" spread="11.02"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="32.23" spread="11.13"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.41" spread="12.01"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="32.65" spread="10.64"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="32.46" spread="11.78"/>
                    <measurement group_id="O6" value="32.51" spread="10.58"/>
                    <measurement group_id="O7" value="33.41" spread="10.10"/>
                    <measurement group_id="O8" value="33.36" spread="10.93"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="33.88" spread="8.90"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.25" spread="10.80"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="35.44" spread="11.16"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="34.30" spread="10.87"/>
                    <measurement group_id="O6" value="33.17" spread="9.43"/>
                    <measurement group_id="O7" value="35.05" spread="10.17"/>
                    <measurement group_id="O8" value="33.99" spread="11.61"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="35.42" spread="10.04"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,44,13,55,64,59,51,12,35,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.69" spread="10.42"/>
                    <measurement group_id="O2" value="28.08" spread="11.07"/>
                    <measurement group_id="O3" value="35.48" spread="11.66"/>
                    <measurement group_id="O4" value="34.92" spread="9.40"/>
                    <measurement group_id="O5" value="36.78" spread="10.75"/>
                    <measurement group_id="O6" value="35.36" spread="10.01"/>
                    <measurement group_id="O7" value="36.80" spread="9.85"/>
                    <measurement group_id="O8" value="38.24" spread="9.46"/>
                    <measurement group_id="O9" value="29.50" spread="12.27"/>
                    <measurement group_id="O10" value="37.17" spread="10.12"/>
                    <measurement group_id="O11" value="37.47" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET</title>
        <description>FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Baseline, Week 2, 12, 24/ET</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 3 mg</title>
            <description>CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 15 mg tablet orally twice daily for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>CP-690,550 20 mg</title>
            <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Placebo to CP-690,550 5 mg (R)</title>
            <description>Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET</title>
          <description>FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here &quot;N&quot; (number of participants analyzed) signifies participants evaluable for this measure and “n” signifies participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="78"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="66"/>
                <count group_id="O11" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=68,0,68,0,68,72,73,78,0,66,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="7.99"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="2.74" spread="7.80"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="3.54" spread="7.71"/>
                    <measurement group_id="O6" value="2.80" spread="7.40"/>
                    <measurement group_id="O7" value="3.68" spread="7.24"/>
                    <measurement group_id="O8" value="3.37" spread="6.56"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="1.61" spread="6.21"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="8.53"/>
                    <measurement group_id="O2" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O3" value="5.79" spread="10.95"/>
                    <measurement group_id="O4" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O5" value="4.90" spread="8.98"/>
                    <measurement group_id="O6" value="2.18" spread="9.25"/>
                    <measurement group_id="O7" value="5.41" spread="9.02"/>
                    <measurement group_id="O8" value="4.51" spread="9.27"/>
                    <measurement group_id="O9" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                    <measurement group_id="O10" value="2.71" spread="9.94"/>
                    <measurement group_id="O11" value="NA">Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=39,20,44,13,55,64,59,50,12,35,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" spread="9.66"/>
                    <measurement group_id="O2" value="3.73" spread="10.35"/>
                    <measurement group_id="O3" value="5.33" spread="9.42"/>
                    <measurement group_id="O4" value="5.62" spread="11.57"/>
                    <measurement group_id="O5" value="7.18" spread="9.08"/>
                    <measurement group_id="O6" value="4.49" spread="9.43"/>
                    <measurement group_id="O7" value="6.54" spread="8.90"/>
                    <measurement group_id="O8" value="6.88" spread="9.28"/>
                    <measurement group_id="O9" value="4.75" spread="10.84"/>
                    <measurement group_id="O10" value="3.23" spread="12.13"/>
                    <measurement group_id="O11" value="4.18" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 1 mg</title>
          <description>CP-690,550 1 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 1 mg to CP-690,550 5 mg (R)</title>
          <description>CP-690,550 1 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.</description>
        </group>
        <group group_id="E3">
          <title>CP-690,550 3 mg</title>
          <description>CP-690,550 3 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E4">
          <title>CP-690,550 3 mg to CP-690,550 5 mg (R)</title>
          <description>CP-690,550 3 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.</description>
        </group>
        <group group_id="E5">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E6">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E7">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 15 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E8">
          <title>CP-690,550 20 mg</title>
          <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 24.</description>
        </group>
        <group group_id="E9">
          <title>CP-690,550 20 mg to CP-690,550 5 mg (R)</title>
          <description>CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 12 followed by CP-690,550 5 mg tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E10">
          <title>Placebo</title>
          <description>Matching placebo tablet orally twice daily up to Week 24.</description>
        </group>
        <group group_id="E11">
          <title>Placebo to CP-690,550 5 mg (R)</title>
          <description>Matching placebo tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST-T change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Palpable purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Venous stasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

